US20220202777A1 - Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators - Google Patents

Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators Download PDF

Info

Publication number
US20220202777A1
US20220202777A1 US17/229,347 US202117229347A US2022202777A1 US 20220202777 A1 US20220202777 A1 US 20220202777A1 US 202117229347 A US202117229347 A US 202117229347A US 2022202777 A1 US2022202777 A1 US 2022202777A1
Authority
US
United States
Prior art keywords
amino
optionally substituted
carbamoyl
bromophenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/229,347
Inventor
Richard L. Beard
Tien T. Duong
John E. Donello
Veena Viswanath
Michael E. Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20220202777(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to US17/229,347 priority Critical patent/US20220202777A1/en
Assigned to ALLERGAN, INC. reassignment ALLERGAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VISWANATH, VEENA, DONELLO, JOHN E., DUONG, TIEN T., GARST, MICHAEL E., BEARD, RICHARD L.
Publication of US20220202777A1 publication Critical patent/US20220202777A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/417Imidazole-alkylamines, e.g. histamine, phentolamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42Y being a hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43Y being a hetero atom
    • C07C323/44X or Y being nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052Val-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • C07K5/06113Asp- or Asn-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
  • the invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with the N-formyl peptide receptor like-1 (FPRL-1) receptor modulation.
  • the N-formyl peptide receptor like-1 (FPRL-1) receptor is a G protein-coupled receptor that is expressed on inflammatory cells such as monocytes and neutrophils, as well as T cells and has been shown to play a critical role in leukocyte trafficking during inflammation and human pathology.
  • FPRL-1 is an exceptionally promiscuous receptor that responds to a large array of exogenous and endogenous ligands, including Serum amyloid A (SAA), chemokine variant sCK ⁇ 8-1, the neuroprotective peptide human, anti-inflammatory eicosanoid lipoxin A4 (LXA4) and glucocorticoid-modulated protein annexin A1.
  • SAA Serum amyloid A
  • LXA4 anti-inflammatory eicosanoid lipoxin A4
  • FPRL-1 transduces anti-inflammatory effects of LXA4 in many systems, but it also can mediate the pro-inflammatory signaling cascade of peptides such as SAA.
  • the ability of the receptor to mediate two opposite effects is proposed to be a result of different receptor domains used by different agonists (Parmentier, Marc et al. Cytokine & Growth Factor Reviews 17 (2006) 501-519).
  • FPRL-1 Activation of FPRL-1 by LXA4 or its analogs and by Annexin I protein has been shown to result in anti-inflammatory activity by promoting active resolution of inflammation which involves inhibition of polymorphonuclear neutrophil (PMN) and eosinophil migration and also stimulate monocyte migration enabling clearance of apoptotic cells from the site of inflammation in a nonphlogistic manner.
  • PMN polymorphonuclear neutrophil
  • FPRL-1 has been shown to inhibit natural killer (NK) cell cytotoxicity and promote activation of T cells which further contributes to down regulation of tissue damaging inflammatory signals.
  • NK natural killer
  • FPRL-1/LXA4 interaction has been shown to be beneficial in experimental models of ischemia reperfusion, angiogenesis, dermal inflammation, chemotherapy-induced alopecia, ocular inflammation such as endotoxin-induced uveitis, corneal wound healing, re-epithelialization etc.
  • FPRL-1 thus represents an important novel pro-resolutionary molecular target for the development of new therapeutic agents in diseases with excessive inflammatory responses.
  • JP 06172288 discloses the preparation of phenylalanine derivatives of general formula:
  • acyl-coenzyme A:cholesterol acyltransferase derivatives useful for the treatment of arteriosclerosis-related various diseases such as angina pectoris, cardiac infarction, temporary ischemic spasm, peripheral thrombosis or obstruction.
  • WO 9965932 discloses tetrapeptides or analogs or peptidomimetics that selectively bind mammalian opioid receptors:
  • EP 457195 discloses the preparation of peptides having endothelin antagonist activity and pharmaceutical compositions comprising them:
  • FR 2533210 discloses L-phenyl alanine derivatives as synthetic sweeteners:
  • WO2005047899 discloses compounds which selectively activate the FPRL-1 receptor represented by the following scaffolds:
  • FPRL-1 modulators A group of amide derivatives of N-urea substituted amino acids, which are potent and selective FPRL-1 modulators, has been discovered. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of FPRL-1 receptor.
  • modulator includes but is not limited to: receptor agonist, antagonist, inverse agonist, inverse antagonist, partial agonist, and partial antagonist.
  • This invention describes compounds of Formula I, which have FPRL-1 receptor biological activity.
  • the compounds in accordance with the present invention are thus of use in medicine, for example in the treatment of humans with diseases and conditions that are alleviated by FPRL-1 modulation.
  • the invention provides a compound represented by Formula I or the individual geometrical isomers, individual enantiomers, individual diastereoisomers, individual tautomers, individual zwitterions or a pharmaceutically acceptable salt thereof:
  • R 1 is optionally substituted C 1-8 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 3-8 cycloalkenyl, —NH 2 , —OH, —O(C 1-8 alkyl),
  • R 2 is optionally substituted C 1-8 alkyl, optionally substituted C 6-10 aryl,
  • R 3 is H, optionally substituted C 1-8 alkyl, halogen, —COOH, —OH, —NH 2 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 3-8 cycloalkenyl;
  • R 4 is H, optionally substituted C 1-8 alkyl, halogen,
  • the invention provides a compound represented by Formula II or the geometrical isomers, enantiomers, diastereoisomers, tautomers, zwitterions, hydrates, crystal forms, solvates or a pharmaceutically acceptable salt thereof:
  • R 1 is optionally substituted C 1-8 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 3-8 cycloalkenyl, —NR 11 R 12 or —OR 13 ;
  • R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl;
  • R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl;
  • R 4 is hydrogen, optionally substituted C 1-8 alkyl
  • R 9 is not optionally substituted benzyl
  • R 11 is not:
  • R 1 is OR 13 ;
  • the invention provides a compound represented by Formula II, wherein: a is 1 and b is 0; R 1 is optionally substituted C 1-8 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 3-8 cycloalkenyl, —NR 11 R 12 or —OR 13 ; R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl; R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl; R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen,
  • R 9 is not optionally substituted benzyl
  • R 11 is not:
  • the invention provides a compound represented by Formula II, wherein: a is 1 and b is 0; R 1 is optionally substituted C 1-8 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 3-8 cycloalkenyl, —NR 11 R 12 or —OR 13 ; R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl; R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl; R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen,
  • R 9 is not optionally substituted benzyl
  • R 11 is not:
  • the invention provides a compound represented by Formula II, wherein: a is 1 and b is 0; R 1 is optionally substituted C 1-8 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 3-8 cycloalkenyl, —NR 11 R 12 or —OR 13 ; R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl; R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl; R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen,
  • R 9 is not optionally substituted benzyl
  • R 11 is not:
  • the invention provides a compound represented by Formula II, wherein: a is 1 and b is 0; R 1 is optionally substituted C 1-8 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 3-8 cycloalkenyl, —NR 11 R 12 or —OR 13 ; R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl; R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl; R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen,
  • R 9 is not optionally substituted benzyl
  • R 11 is not:
  • the invention provides a compound represented by Formula II, wherein a is 1 and b is 0; R 1 is optionally substituted C 1-8 alkyl, —NR 11 R 12 or —OR 13 ; R 2 is optionally substituted C 1-8 alkyl; R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 ; R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 ; R 5 is halogen, —CF 3 or —S(O) n R 14 ; n is 0, 1 or 2; R 6 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 ; R 7 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 ,
  • R 11 is not:
  • the invention provides a compound represented by Formula II, wherein a is 1 and b is 0; R 1 is optionally substituted C 1-8 alkyl, —NR 11 R 12 or —OR 13 ; R 2 is optionally substituted C 1-8 alkyl; R 3 is hydrogen or halogen; R 4 is hydrogen; R 5 is halogen, —CF 3 or —S(O) n R 14 ; n is 0, 1 or 2; R 6 is hydrogen; R 7 is hydrogen; R 8 is hydrogen, optionally substituted C 1-8 alkyl; R 9 is hydrogen, optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl; R 10 is hydrogen, optionally substituted C 1-8 alkyl; R 11 is hydrogen or optionally substituted C 1-8 alkyl; R 12 is hydrogen or optionally substituted C 1-8 alkyl; R 13 is hydrogen or optionally substituted C 1-8 alkyl; R 14 is hydrogen or optionally substituted C 1-8 alkyl; with the provisos:
  • R 11 is not:
  • the invention provides a compound represented by Formula II, wherein a is 0 and b is 1; R 1 is —OR 13 ; R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl; R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl; R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl; R 5 is halogen, —
  • the invention provides a compound represented by Formula II, wherein a is 0 and bis 1; R 1 is —OR 13 ; R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl; R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl; R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl; R 5 is halogen; R 6 is hydrogen
  • the invention provides a compound represented by Formula II, wherein: a is 0 and b is 1; R 1 is —OR 13 ; R 2 is optionally substituted C 1-8 alkyl; R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen; R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen; R 5 is halogen, —CF 3 or —S(O) n R 14 ; n is 0, 1 or 2; R 6 is hydrogen, optionally substituted C 1-8 alkyl, halogen; R 7 is hydrogen, optionally substituted C 1-8 alkyl, halogen; R 8 is hydrogen; R 9 is hydrogen; R 10 is hydrogen, optionally substituted C 1-8 alkyl; R 9a is hydrogen, optionally substituted C 1-8 alkyl; R 10a is hydrogen, optionally substituted C 1-8 alkyl; R 13 is hydrogen or optionally substituted C 1-8 alkyl; and R 14 is hydrogen, CF 3 or optionally substituted C
  • the invention provides a compound represented by Formula II, wherein: a is 0 and bis 1; R 1 is —OR 13 ; R 2 is optionally substituted C 1-8 alkyl; R 3 is hydrogen or halogen; R 4 is hydrogen; R 5 is halogen; R 6 is hydrogen; R 7 is hydrogen; R 8 is hydrogen; R 9 is hydrogen; R 10 is hydrogen or optionally substituted C 1-8 alkyl; R 9a is hydrogen or optionally substituted C 1-8 alkyl; R 10a is hydrogen or optionally substituted C 1-8 alkyl; and R 13 is hydrogen; and the compound of Formula II is not of structure:
  • the invention provides a compound represented by Formula II, wherein: a is 0 and b is 1; R 1 is —OR 13 ; R 2 is optionally substituted C 1-8 alkyl; R 3 is hydrogen or halogen; R 4 is hydrogen; R 5 is halogen; R 6 is hydrogen; R 7 is hydrogen; R 8 is hydrogen; R 9 is hydrogen; R 10 is hydrogen or optionally substituted C 1-8 alkyl; R 9a is optionally substituted C 1-8 alkyl; R 10a is optionally substituted C 1-8 alkyl; and R 13 is hydrogen.
  • the invention provides a compound represented by Formula II, wherein a is 1 and b is 1; R 1 is optionally substituted C 1-8 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 3-8 cycloalkenyl, —NR 11 R 12 or —OR 13 ; R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl; R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl; R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —CO
  • the invention provides a compound represented by Formula II, wherein a is 1 and b is 1; R 1 is optionally substituted C 1-8 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 3-8 cycloalkenyl, —NR 11 R 12 or —OR 13 ; R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl; R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl; R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —CO
  • the invention provides a compound represented by Formula II, wherein a is 1 and b is 1; R 1 is optionally substituted C 1-8 alkyl, —NR 11 R 12 or —OR 13 ; R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl; R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen; R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen; R 5 is halogen, —CF 3 or —S(O) n R 14 ; n is 0, 1 or 2; R 6 is hydrogen, optionally substituted C 1-8 alkyl, halogen; R 7 is hydrogen, optionally substituted C 1-8 alkyl, halogen; R 8 is hydrogen; R 9 is hydrogen, optionally substituted C 1-8 alkyl; R 10 is hydrogen, optionally substituted C 1-8 alkyl; R 9a is hydrogen, optionally substituted C 1-8 alkyl; R 10a is hydrogen, optionally substituted C 1-8
  • the invention provides a compound represented by Formula II, wherein a is 1 and b is 1; R 1 is —OR 13 ; R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl; R 3 is hydrogen; R 4 is hydrogen; R 5 is halogen; R 6 is hydrogen; R 7 is hydrogen; R 8 is hydrogen; R 9 is hydrogen; R 10 is hydrogen; R 9a is hydrogen; R 10a is hydrogen; and R 13 is hydrogen or optionally substituted C 1-8 alkyl; and with the proviso: that R 11 is not:
  • alkyl refers to saturated, monovalent or divalent hydrocarbon moieties having linear or branched moieties or combinations thereof and containing 1 to 8 carbon atoms.
  • One methylene (—CH 2 —) group, of the alkyl group can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C 3-8 cycloalkyl, by a divalent heterocycle, or by a divalent aryl group.
  • Alkyl groups can have one or more chiral centers.
  • Alkyl groups can be independently substituted by halogen atoms, hydroxyl groups, cycloalkyl groups, amino groups, heterocyclic groups, aryl groups, carboxylic acid groups, phosphonic acid groups, sulphonic acid groups, phosphoric acid groups, nitro groups, amide groups, sulfonamide groups.
  • cycloalkyl refers to a monovalent or divalent group of 3 to 8 carbon atoms derived from a saturated cyclic hydrocarbon.
  • Cycloalkyl groups can be monocyclic or polycyclic. Cycloalkyl can be independently substituted by halogen atoms, sulfonyl C 1-8 alkyl groups, sulfoxide C 1-8 alkyl groups, sulfonamide groups, nitro groups, cyano groups, —OC 1-8 alkyl groups, —SC 1-8 alkyl groups, —C 1-8 alkyl groups, —C 2-6 alkenyl groups, —C 2-6 alkynyl groups, ketone groups, alkylamino groups, amino groups, aryl groups, C 3-8 cycloalkyl groups or hydroxyl groups.
  • cycloalkenyl refers to a monovalent or divalent group of 3 to 8 carbon atoms derived from a saturated cycloalkyl having at least one double bond. Cycloalkenyl groups can be monocyclic or polycyclic.
  • Cycloalkenyl groups can be independently substituted by halogen atoms, sulfonyl groups, sulfoxide groups, nitro groups, cyano groups, —OC 1-6 alkyl groups, —SC 1-6 alkyl groups, —C 1-6 alkyl groups, —C 2-6 alkenyl groups, —C 2-6 alkynyl groups, ketone groups, alkylamino groups, amino groups, aryl groups, C 3-8 cycloalkyl groups or hydroxyl groups.
  • halogen refers to an atom of chlorine, bromine, fluorine, iodine.
  • alkenyl refers to a monovalent or divalent hydrocarbon radical having 2 to 6 carbon atoms, derived from a saturated alkyl, having at least one double bond.
  • One methylene (—CH 2 —) group, of the alkenyl can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C 3-8 cycloalkyl, by a divalent heterocycle, or by a divalent aryl group.
  • C 2-6 alkenyl can be in the E or Z configuration.
  • Alkenyl groups can be substituted by alkyl groups, as defined above or by halogen atoms.
  • alkynyl refers to a monovalent or divalent hydrocarbon radical having 2 to 6 carbon atoms, derived from a saturated alkyl, having at least one triple bond.
  • One methylene (—CH 2 —) group, of the alkynyl can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C 3-8 cycloalkyl, by a divalent heterocycle, or by a divalent aryl group.
  • Alkynyl groups can be substituted by alkyl groups, as defined above, or by halogen atoms.
  • heterocycle refers to a 3 to 10 membered ring, which can be aromatic or non-aromatic, saturated or unsaturated, containing at least one heteroatom selected form oxygen, nitrogen, sulfur, or combinations of at least two thereof, interrupting the carbocyclic ring structure.
  • the heterocyclic ring can be interrupted by a C ⁇ O; the S and N heteroatoms can be oxidized.
  • Heterocycles can be monocyclic or polycyclic.
  • Heterocyclic ring moieties can be substituted by halogen atoms, sulfonyl groups, sulfoxide groups, nitro groups, cyano groups, —OC 1-6 alkyl groups, —SC 1-6 alkyl groups, —C 1-8 alkyl groups, —C 2-6 alkenyl groups, —C 2-6 alkynyl groups, ketone groups, alkylamino groups, amino groups, aryl groups, C 3-8 cycloalkyl groups or hydroxyl groups.
  • aryl refers to an organic moiety derived from an aromatic hydrocarbon consisting of a ring containing 6 to 10 carbon atoms, by removal of one hydrogen atom.
  • Aryl can be substituted by halogen atoms, sulfonyl C 1-6 alkyl groups, sulfoxide C 1-6 alkyl groups, sulfonamide groups, carboxylic acid groups, C 1-6 alkyl carboxylates (ester) groups, amide groups, nitro groups, cyano groups, —OC 1-6 alkyl groups, —SC 1-6 alkyl groups, —C 1-6 alkyl groups, —C 2-6 alkenyl groups, —C 2-6 alkynyl groups, ketone groups, aldehydes, alkylamino groups, amino groups, aryl groups, C 3-8 cycloalkyl groups or hydroxyl groups.
  • Aryls can be monocyclic or polycyclic.
  • hydroxyl as used herein, represents a group of formula “—OH”.
  • carbonyl as used herein, represents a group of formula “—C(O)—”.
  • ketone represents an organic compound having a carbonyl group linked to a carbon atom such as —(CO)R x wherein R x can be alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • amine as used herein, represents a group of formula “—NR x R y ”, wherein R x and R y can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • sulfonyl as used herein, represents a group of formula “—SO 2 —”.
  • sulfonate represents a group of the formula “—S(O) 2 —O—”.
  • carboxylic acid as used herein, represents a group of formula “—C(O)OH”.
  • nitro as used herein, represents a group of formula “—NO 2 ”.
  • cyano as used herein, represents a group of formula “—CN”.
  • amide as used herein, represents a group of formula “—C(O)NR x R y ” wherein R x and R y can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • sulfonamide represents a group of formula “—S(O) 2 NR x R y ” wherein R x and R y can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • sulfoxide as used herein, represents a group of formula “—S(O)—”.
  • phosphonic acid as used herein, represents a group of formula “—P(O)(OH) 2 ”.
  • phosphoric acid as used herein, represents a group of formula “—OP(O)(OH) 2 ”.
  • sulphonic acid as used herein, represents a group of formula “—S(O) 2 OH”.
  • N represents a nitrogen atom
  • the invention discloses compounds
  • Some compounds of Formula I and of Formula II and some of their intermediates have at least one asymmetric center in their structure.
  • This asymmetric center may be present in an R or S configuration, said R and S notation is used in correspondence with the rules described in Pure Appli. Chem. (1976), 45, 11-13.
  • pharmaceutically acceptable salts refers to salts or complexes that retain the desired biological activity of the above identified compounds and exhibit minimal or no undesired toxicological effects.
  • pharmaceutically acceptable salts according to the invention include therapeutically active, non-toxic base or acid salt forms, which the compounds of Formula I and of Formula II are able to form.
  • the acid addition salt form of a compound of Formula I and of Formula II that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an inorganic acid, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; or an organic acid such as for example, acetic acid, hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, malonic acid, fumaric acid, maleic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, citric acid, methylsulfonic acid, ethanesulfonic acid, benzenesulfonic acid, formic and the like (Handbook of Pharmaceutical Salts, P. Heinrich Stahl & Camille G. Wermuth (Eds), Verlag Helvetica Chemica Acta-Zirich, 2002, 329-3
  • the base addition salt form of a compound of Formula I and of Formula II that occurs in its acid form can be obtained by treating the acid with an appropriate base such as an inorganic base, for example, sodium hydroxide, magnesium hydroxide, potassium hydroxide, Calcium hydroxide, ammonia and the like; or an organic base such as for example, L-Arginine, ethanolamine, betaine, benzathine, morpholine and the like.
  • an appropriate base such as an inorganic base, for example, sodium hydroxide, magnesium hydroxide, potassium hydroxide, Calcium hydroxide, ammonia and the like
  • an organic base such as for example, L-Arginine, ethanolamine, betaine, benzathine, morpholine and the like.
  • solvates include for example hydrates, alcoholates and the like.
  • the compounds of the invention are indicated for use in treating or preventing conditions in which there is likely to be a component involving the N-formyl peptide receptor like-1 receptor.
  • compositions including at least one compound of the invention in a pharmaceutically acceptable carrier.
  • Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one compound of the invention.
  • N-formyl peptide receptor like-1 receptor modulators are ocular inflammatory diseases including, but not limited to, wet and dry age-related macular degeneration (ARMD), uveitis, dry eye, Keratitis, allergic eye disease and conditions affecting the posterior part of the eye, such as maculopathies and retinal degeneration including non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, diabetic retinopathy (proliferative), retinopathy of prematurity (ROP), acute macular neuroretinopathy, central serous chorioretinopathy, cystoid macular edema, and diabetic macular edema; infectious keratitis, uveitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, uveitis, retinitis, and choroiditis such as acute multifocal placoid pigment epitheliopathy, Be
  • Pharmacology & Therapeutics 127 (2010) 175-188. These compounds are useful for the treatment of mammals, including humans, with a range of conditions and diseases that are alleviated by the N-formyl peptide receptor like-1 receptor modulation: including, but not limited to the treatment of wet and dry age-related macular degeneration (ARMD), diabetic retinopathy (proliferative), retinopathy of prematurity (ROP), diabetic macular edema, uveitis, retinal vein occlusion, cystoids macular edema, glaucoma, branch vein occlusion, Best's vitelliform macular degeneration, retinitis pigmentosa, proliferative vitreoretinopathy (PVR), and any other degenerative disease of either the photoreceptors or the RPE.
  • AMD age-related macular degeneration
  • ROP retinopathy of prematurity
  • PVR proliferative vitreoretinopathy
  • methods for treating disorders associated with modulation of the FPRL-1 receptor can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of at least one compound of the invention, or any combination thereof, or pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual isomers, enantiomers, and diastereomers thereof.
  • the present invention concerns the use of a compound of Formula I and of Formula II or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of ocular inflammatory diseases including, but not limited to, wet and dry age-related macular degeneration (ARMD), uveitis, dry eye, Keratitis, allergic eye disease and conditions affecting the posterior part of the eye, such as maculopathies and retinal degeneration including non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, diabetic retinopathy (proliferative), retinopathy of prematurity (ROP), acute macular neuroretinopathy, central serous chorioretinopathy, cystoid macular edema, and diabetic macular edema; infectious keratitis, uveitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, uveitis, retinitis, and choroidit
  • the actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the severity of the condition, the age and weight of the patient, the patient's general physical condition, the cause of the condition, and the route of administration.
  • the patient will be administered the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like, or other routes may be desirable or necessary, particularly if the patient suffers from nausea.
  • routes may include, without exception, transdermal, parenteral, subcutaneous, intranasal, via an implant stent, intrathecal, intravitreal, topical to the eye, back to the eye, intramuscular, intravenous, and intrarectal modes of delivery.
  • the formulations may be designed to delay release of the active compound over a given period of time, or to carefully control the amount of drug released at a given time during the course of therapy.
  • compositions including at least one compound of the invention in a pharmaceutically acceptable carrier thereof.
  • pharmaceutically acceptable means the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a patch, a micelle, a liposome, and the like, wherein the resulting composition contains one or more compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications.
  • Invention compounds may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.
  • the carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form.
  • Invention compounds are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.
  • compositions containing invention compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets containing invention compounds in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods.
  • the excipients used may be, for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • formulations for oral use may be in the form of hard gelatin capsules wherein the invention compounds are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the invention compounds are mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin.
  • water or an oil medium for example, peanut oil, liquid paraffin or olive oil.
  • the pharmaceutical compositions may be in the form of a sterile injectable suspension.
  • This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • Sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.
  • compositions may be prepared by mixing the invention compounds with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.
  • a suitable non-irritating excipient such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.
  • the compounds and pharmaceutical compositions described herein are useful as medicaments in mammals, including humans, for treatment of diseases and/or alleviations of conditions which are responsive to treatment by agonists or functional antagonists of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
  • FPRL-1 N-formyl peptide receptor like-1
  • methods for treating a disorder associated with modulation of the N-formyl peptide receptor like-1 (FPRL-1) receptor can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one invention compound.
  • the term “therapeutically effective amount” means the amount of the pharmaceutical composition that will elicit the biological or medical response of a subject in need thereof that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • the subject in need thereof is a mammal. In some embodiments, the mammal is human.
  • the present invention concerns also processes for preparing the compounds of Formula I.
  • the compounds of formula I according to the invention can be prepared analogously to conventional methods as understood by the person skilled in the art of synthetic organic chemistry. Synthetic Scheme 1 set forth below, illustrates how the compounds according to the invention can be made.
  • the t-butyl ester protecting group is then removed under acidic conditions to give the amino acid urea.
  • the carboxylic acid group is then converted to an amide by treating the compound with activating reagents, such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) and Hydroxybenzotriazole (HOBt) in the presence of an amine, or by other methods known to those skilled in the art.
  • activating reagents such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) and Hydroxybenzotriazole (HOBt) in the presence of an amine, or by other methods known to those skilled in the art.
  • Some of the compounds of the invention may form salts with pharmaceutically acceptable acids or bases, and such pharmaceutically acceptable salts of the compounds described herein are also within the scope of the invention.
  • the present invention includes all pharmaceutically acceptable isotopically enriched compounds.
  • Any compound of the invention may contain one or more isotopic atoms enriched or different than the natural ratio such as deuterium 2 H (or D) in place of hydrogen 1H (or H) or use of 13 C enriched material in place of 12 C and the like. Similar substitutions can be employed for N, O and S.
  • the use of isotopes may assist in analytical as well as therapeutic aspects of the invention. For example, use of deuterium may increase the in vivo half-life by altering the metabolism (rate) of the compounds of the invention.
  • These compounds can be prepared in accord with the preparations described by use of isotopically enriched reagents.
  • Biological activity of compounds according to Formula II is set forth in Table 5 below.
  • CHO-G ⁇ 16 cells stably expressing FPRL1 were cultured in (F12, 10% FBS, 1% PSA, 400 ⁇ g/ml geneticin and 50 ⁇ g/ml hygromycin) and HEK-Gqi5 cells stable expressing FPR1 were cultured in (DMEM high glucose, (0% FBS, 1% PSA, 400 ⁇ g/ml geneticin and 50 ⁇ g/ml hygromycin).
  • DMEM high glucose (0% FBS, 1% PSA, 400 ⁇ g/ml geneticin and 50 ⁇ g/ml hygromycin).
  • 18,000 cells/well were plated in a 384-well clear bottom poly-d-lysine coated plate.

Abstract

The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 16/215,400, filed Dec. 10, 2018, which is a continuation of U.S. patent application Ser. No. 15/949,335, filed Apr. 10, 2018, now U.S. Pat. No. 10,172,832, issued Jan. 8, 2019, which is a continuation of U.S. patent application Ser. No. 15/408,643, filed Jan. 18, 2017, now U.S. Pat. No. 9,974,772, issued May 22, 2018, which is a continuation of U.S. patent application Ser. No. 15/138,823, filed Apr. 26, 2016, now U.S. Pat. No. 9,579,307, issued on Feb. 28, 2017, which is a continuation of U.S. patent application Ser. No. 14/608,503, filed Jan. 29, 2015, now U.S. Pat. No. 9,351,948, issued May 31, 2016, which is a continuation of U.S. patent application Ser. No. 14/102,145, filed Dec. 10, 2013, now U.S. Pat. No. 8,993,780, issued Mar. 31, 2015, which is a divisional of U.S. patent application Ser. No. 13/658,523, filed Oct. 23, 2012, now U.S. Pat. No. 8,658,803, issued Feb. 25, 2014, which claims the benefit of U.S. Provisional Application Ser. No. 61/551,772, filed Oct. 26, 2011, each of which are hereby incorporated by reference in their entireties, and serve as the basis for a priority and/or benefit claim of the present application.
  • FIELD OF THE INVENTION
  • The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with the N-formyl peptide receptor like-1 (FPRL-1) receptor modulation.
  • BACKGROUND OF THE INVENTION
  • The N-formyl peptide receptor like-1 (FPRL-1) receptor is a G protein-coupled receptor that is expressed on inflammatory cells such as monocytes and neutrophils, as well as T cells and has been shown to play a critical role in leukocyte trafficking during inflammation and human pathology. FPRL-1 is an exceptionally promiscuous receptor that responds to a large array of exogenous and endogenous ligands, including Serum amyloid A (SAA), chemokine variant sCKβ8-1, the neuroprotective peptide human, anti-inflammatory eicosanoid lipoxin A4 (LXA4) and glucocorticoid-modulated protein annexin A1. FPRL-1 transduces anti-inflammatory effects of LXA4 in many systems, but it also can mediate the pro-inflammatory signaling cascade of peptides such as SAA. The ability of the receptor to mediate two opposite effects is proposed to be a result of different receptor domains used by different agonists (Parmentier, Marc et al. Cytokine & Growth Factor Reviews 17 (2006) 501-519).
  • Activation of FPRL-1 by LXA4 or its analogs and by Annexin I protein has been shown to result in anti-inflammatory activity by promoting active resolution of inflammation which involves inhibition of polymorphonuclear neutrophil (PMN) and eosinophil migration and also stimulate monocyte migration enabling clearance of apoptotic cells from the site of inflammation in a nonphlogistic manner. In addition, FPRL-1 has been shown to inhibit natural killer (NK) cell cytotoxicity and promote activation of T cells which further contributes to down regulation of tissue damaging inflammatory signals. FPRL-1/LXA4 interaction has been shown to be beneficial in experimental models of ischemia reperfusion, angiogenesis, dermal inflammation, chemotherapy-induced alopecia, ocular inflammation such as endotoxin-induced uveitis, corneal wound healing, re-epithelialization etc. FPRL-1 thus represents an important novel pro-resolutionary molecular target for the development of new therapeutic agents in diseases with excessive inflammatory responses.
  • JP 06172288 discloses the preparation of phenylalanine derivatives of general formula:
  • Figure US20220202777A1-20220630-C00001
  • as inhibitors of acyl-coenzyme A:cholesterol acyltransferase derivatives useful for the treatment of arteriosclerosis-related various diseases such as angina pectoris, cardiac infarction, temporary ischemic spasm, peripheral thrombosis or obstruction.
  • Journal of Combinatorial Chemistry (2007), 9(3), 370-385 teaches a thymidinyl dipeptide urea library with structural similarity to the nucleoside peptide class of antibiotics:
  • Figure US20220202777A1-20220630-C00002
  • WO 9965932 discloses tetrapeptides or analogs or peptidomimetics that selectively bind mammalian opioid receptors:
  • Figure US20220202777A1-20220630-C00003
  • Helvetica Chimica Acta (1998), 81(7), 1254-1263 teaches the synthesis and spectroscopic characterization of 4-chlorophenyl isocyanate (1-chloro-4-isocyanatobenzene) adducts with amino acids as potential dosimeters for the biomonitoring of isocyanate exposure:
  • Figure US20220202777A1-20220630-C00004
  • EP 457195 discloses the preparation of peptides having endothelin antagonist activity and pharmaceutical compositions comprising them:
  • Figure US20220202777A1-20220630-C00005
  • Yingyong Huaxue (1990), 7(1), 1-9 teaches the structure-activity relations of di- and tripeptide sweeteners and of L-phenyl alanine derivatives:
  • Figure US20220202777A1-20220630-C00006
  • FR 2533210 discloses L-phenyl alanine derivatives as synthetic sweeteners:
  • Figure US20220202777A1-20220630-C00007
  • WO2005047899 discloses compounds which selectively activate the FPRL-1 receptor represented by the following scaffolds:
  • Figure US20220202777A1-20220630-C00008
  • SUMMARY OF THE INVENTION
  • A group of amide derivatives of N-urea substituted amino acids, which are potent and selective FPRL-1 modulators, has been discovered. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of FPRL-1 receptor. The term “modulator” as used herein, includes but is not limited to: receptor agonist, antagonist, inverse agonist, inverse antagonist, partial agonist, and partial antagonist.
  • This invention describes compounds of Formula I, which have FPRL-1 receptor biological activity. The compounds in accordance with the present invention are thus of use in medicine, for example in the treatment of humans with diseases and conditions that are alleviated by FPRL-1 modulation.
  • In one aspect, the invention provides a compound represented by Formula I or the individual geometrical isomers, individual enantiomers, individual diastereoisomers, individual tautomers, individual zwitterions or a pharmaceutically acceptable salt thereof:
  • Figure US20220202777A1-20220630-C00009
  • wherein:
    a is 0 or 1;
    b is 0, 1, 2, 3 or 4;
    R1 is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, —NH2, —OH, —O(C1-8 alkyl),
    R2 is optionally substituted C1-8 alkyl, optionally substituted C6-10 aryl,
    R3 is H, optionally substituted C1-8 alkyl, halogen, —COOH, —OH, —NH2, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl;
    R4 is H, optionally substituted C1-8 alkyl, halogen, —COOH, —OH, —NH2, —NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl;
    R5 is optionally substituted C1-8 alkyl, halogen, —COOH, —OH, —NH2, —NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl;
    R6 is H, optionally substituted C1-8 alkyl, halogen, —COOH, —OH, —NH2, —NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl;
    R7 is H, optionally substituted C1-8 alkyl, halogen, —COOH, —OH, —NH2, —NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl;
    and compounds:
  • Figure US20220202777A1-20220630-C00010
  • In another aspect, the invention provides a compound represented by Formula II or the geometrical isomers, enantiomers, diastereoisomers, tautomers, zwitterions, hydrates, crystal forms, solvates or a pharmaceutically acceptable salt thereof:
  • Figure US20220202777A1-20220630-C00011
  • wherein:
    a is 1 and b is 0;
    a is 0 and b is 1;
    a is 1 and b is 1;
    R1 is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, —NR11R12 or —OR13;
    R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R5 is halogen, —CF3 or —S(O)nR14;
    n is 0, 1 or 2;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R8 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R14 is hydrogen, CF3 or optionally substituted C1-8 alkyl;
    R15 is hydrogen or optionally substituted C1-8 alkyl;
    with the provisos:
    a). when a=1 and b=0 then:
  • R9 is not optionally substituted benzyl; and
  • R11 is not:
  • Figure US20220202777A1-20220630-C00012
  • and
  • the compound of Formula II is not of structures:
  • Figure US20220202777A1-20220630-C00013
    Figure US20220202777A1-20220630-C00014
  • and
    b). when a=0 and b=1 then:
  • R1 is OR13; and
  • the compound of Formula II is not of structure:
  • Figure US20220202777A1-20220630-C00015
  • c). when a=1 and b=1 then:
      • R11 is not:
  • Figure US20220202777A1-20220630-C00016
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein:
    a is 1 and b is 0;
    R1 is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, —NR11R12 or —OR13;
    R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R5 is halogen, —CF3 or —S(O)nR14;
    n is 0, 1 or 2;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R8 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R14 is hydrogen, CF3 or optionally substituted C1-8 alkyl;
    R15 is hydrogen or optionally substituted C1-8 alkyl;
    with the provisos:
  • R9 is not optionally substituted benzyl; and
  • R11 is not:
  • Figure US20220202777A1-20220630-C00017
  • and
  • the compound of Formula II is not of structures:
  • Figure US20220202777A1-20220630-C00018
    Figure US20220202777A1-20220630-C00019
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein:
    a is 1 and b is 0;
    R1 is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, —NR11R12 or —OR13;
    R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R5 is —S(O)nR14;
    n is 0, 1 or 2;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R8 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R14 is hydrogen, CF3 or optionally substituted C1-8 alkyl;
    R15 is hydrogen or optionally substituted C1-8 alkyl;
    with the provisos:
  • R9 is not optionally substituted benzyl; and
  • R11 is not:
  • Figure US20220202777A1-20220630-C00020
  • and
  • the compound of Formula II is not of structures:
  • Figure US20220202777A1-20220630-C00021
    Figure US20220202777A1-20220630-C00022
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein:
    a is 1 and b is 0;
    R1 is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, —NR11R12 or —OR13;
    R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R5 is —CF3;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R8 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R15 is hydrogen or optionally substituted C1-8 alkyl;
    with the provisos:
  • R9 is not optionally substituted benzyl; and
  • R11 is not:
  • Figure US20220202777A1-20220630-C00023
  • and
  • the compound of Formula II is not of structures:
  • Figure US20220202777A1-20220630-C00024
    Figure US20220202777A1-20220630-C00025
  • In another aspect, the invention provides a compound represented by Formula II, wherein: a is 1 and b is 0;
    R1 is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, —NR11R12 or —OR13;
    R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R5 is halogen;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R8 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R15 is hydrogen or optionally substituted C1-8 alkyl;
    with the provisos:
  • R9 is not optionally substituted benzyl;
  • and the compound of Formula II is not of structures:
  • Figure US20220202777A1-20220630-C00026
    Figure US20220202777A1-20220630-C00027
  • and
  • R11 is not:
  • Figure US20220202777A1-20220630-C00028
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein
    a is 1 and b is 0;
    R1 is optionally substituted C1-8 alkyl, —NR11R12 or —OR13;
    R2 is optionally substituted C1-8 alkyl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12;
    R5 is halogen, —CF3 or —S(O)nR14;
    n is 0, 1 or 2;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12;
    R8 is hydrogen or optionally substituted C1-8 alkyl;
    R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10 is hydrogen or optionally substituted C1-8;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R14 is hydrogen or optionally substituted C1-8 alkyl;
    R15 is hydrogen or optionally substituted C1-8 alkyl;
    with the provisos:
    R9 is not optionally substituted benzyl;
    and the compound of Formula II is not of structures:
  • Figure US20220202777A1-20220630-C00029
    Figure US20220202777A1-20220630-C00030
  • and
  • R11 is not:
  • Figure US20220202777A1-20220630-C00031
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein
    a is 1 and b is 0;
    R1 is optionally substituted C1-8 alkyl, —NR11R12 or —OR13;
    R2 is optionally substituted C1-8 alkyl;
    R3 is hydrogen or halogen;
    R4 is hydrogen;
    R5 is halogen, —CF3 or —S(O)nR14;
    n is 0, 1 or 2;
    R6 is hydrogen;
    R7 is hydrogen;
    R8 is hydrogen, optionally substituted C1-8 alkyl;
    R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10 is hydrogen, optionally substituted C1-8 alkyl;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R14 is hydrogen or optionally substituted C1-8 alkyl;
    with the provisos:
    R9 is not optionally substituted benzyl;
    and the compound of Formula II is not of structures:
  • Figure US20220202777A1-20220630-C00032
    Figure US20220202777A1-20220630-C00033
  • and
  • R11 is not:
  • Figure US20220202777A1-20220630-C00034
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein
    a is 0 and b is 1;
    R1 is —OR13;
    R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R5 is halogen, —CF3 or —S(O)nR14;
    n is 0, 1 or 2;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R8 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R14 is hydrogen, CF3 or optionally substituted C1-8 alkyl;
    R15 is hydrogen or optionally substituted C1-8 alkyl; and
    the compound of Formula II is not of structure:
  • Figure US20220202777A1-20220630-C00035
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein
    a is 0 and bis 1;
    R1 is —OR13;
    R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R5 is halogen;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R8 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R15 is hydrogen or optionally substituted C1-8 alkyl; and
    the compound of Formula II is not of structure:
  • Figure US20220202777A1-20220630-C00036
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein:
    a is 0 and b is 1;
    R1 is —OR13;
    R2 is optionally substituted C1-8 alkyl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen;
    R5 is halogen, —CF3 or —S(O)nR14;
    n is 0, 1 or 2;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen;
    R8 is hydrogen;
    R9 is hydrogen;
    R10 is hydrogen, optionally substituted C1-8 alkyl;
    R9a is hydrogen, optionally substituted C1-8 alkyl;
    R10a is hydrogen, optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl; and
    R14 is hydrogen, CF3 or optionally substituted C1-8 alkyl; and
    the compound of Formula II is not of structure:
  • Figure US20220202777A1-20220630-C00037
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein:
    a is 0 and bis 1;
    R1 is —OR13;
    R2 is optionally substituted C1-8 alkyl;
    R3 is hydrogen or halogen;
    R4 is hydrogen;
    R5 is halogen;
    R6 is hydrogen;
    R7 is hydrogen;
    R8 is hydrogen;
    R9 is hydrogen;
    R10 is hydrogen or optionally substituted C1-8 alkyl;
    R9a is hydrogen or optionally substituted C1-8 alkyl;
    R10a is hydrogen or optionally substituted C1-8 alkyl; and
    R13 is hydrogen; and
    the compound of Formula II is not of structure:
  • Figure US20220202777A1-20220630-C00038
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein:
    a is 0 and b is 1;
    R1 is —OR13;
    R2 is optionally substituted C1-8 alkyl;
    R3 is hydrogen or halogen;
    R4 is hydrogen;
    R5 is halogen;
    R6 is hydrogen;
    R7 is hydrogen;
    R8 is hydrogen;
    R9 is hydrogen;
    R10 is hydrogen or optionally substituted C1-8 alkyl;
    R9a is optionally substituted C1-8 alkyl;
    R10a is optionally substituted C1-8 alkyl; and
    R13 is hydrogen.
    In another aspect, the invention provides a compound represented by Formula II,
    wherein
    a is 1 and b is 1;
    R1 is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, —NR11R12 or —OR13;
    R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R5 is halogen, —CF3 or —S(O)nR14;
    n is 0, 1 or 2;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R8 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R14 is hydrogen or optionally substituted C1-8 alkyl; and
    R15 is hydrogen or optionally substituted C1-8 alkyl; and
    with the proviso:
    that R11 is not:
  • Figure US20220202777A1-20220630-C00039
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein
    a is 1 and b is 1;
    R1 is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, —NR11R12 or —OR13;
    R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R5 is halogen;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen, —COOR15, —OR13, —NR11R12, NO2, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
    R8 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R10 is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R9a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl; R10a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R15 is hydrogen or optionally substituted C1-8 alkyl; and
    with the proviso:
    that R11 is not:
  • Figure US20220202777A1-20220630-C00040
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein
    a is 1 and b is 1;
    R1 is optionally substituted C1-8 alkyl, —NR11R12 or —OR13;
    R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R3 is hydrogen, optionally substituted C1-8 alkyl, halogen;
    R4 is hydrogen, optionally substituted C1-8 alkyl, halogen;
    R5 is halogen, —CF3 or —S(O)nR14;
    n is 0, 1 or 2;
    R6 is hydrogen, optionally substituted C1-8 alkyl, halogen;
    R7 is hydrogen, optionally substituted C1-8 alkyl, halogen;
    R8 is hydrogen;
    R9 is hydrogen, optionally substituted C1-8 alkyl;
    R10 is hydrogen, optionally substituted C1-8 alkyl;
    R9a is hydrogen, optionally substituted C1-8 alkyl;
    R10a is hydrogen, optionally substituted C1-8 alkyl;
    R11 is hydrogen or optionally substituted C1-8 alkyl;
    R12 is hydrogen or optionally substituted C1-8 alkyl;
    R13 is hydrogen or optionally substituted C1-8 alkyl;
    R14 is hydrogen or optionally substituted C1-8 alkyl; and
    R15 is hydrogen or optionally substituted C1-8 alkyl;
    with the proviso:
    that R11 is not:
  • Figure US20220202777A1-20220630-C00041
  • In another aspect, the invention provides a compound represented by Formula II,
    wherein
    a is 1 and b is 1;
    R1 is —OR13;
    R2 is optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
    R3 is hydrogen;
    R4 is hydrogen;
    R5 is halogen;
    R6 is hydrogen;
    R7 is hydrogen;
    R8 is hydrogen;
    R9 is hydrogen;
    R10 is hydrogen;
    R9a is hydrogen;
    R10a is hydrogen; and
    R13 is hydrogen or optionally substituted C1-8 alkyl; and
    with the proviso:
    that R11 is not:
  • Figure US20220202777A1-20220630-C00042
  • The term “alkyl”, as used herein, refers to saturated, monovalent or divalent hydrocarbon moieties having linear or branched moieties or combinations thereof and containing 1 to 8 carbon atoms. One methylene (—CH2—) group, of the alkyl group can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C3-8cycloalkyl, by a divalent heterocycle, or by a divalent aryl group. Alkyl groups can have one or more chiral centers. Alkyl groups can be independently substituted by halogen atoms, hydroxyl groups, cycloalkyl groups, amino groups, heterocyclic groups, aryl groups, carboxylic acid groups, phosphonic acid groups, sulphonic acid groups, phosphoric acid groups, nitro groups, amide groups, sulfonamide groups.
  • The term “cycloalkyl”, as used herein, refers to a monovalent or divalent group of 3 to 8 carbon atoms derived from a saturated cyclic hydrocarbon. Cycloalkyl groups can be monocyclic or polycyclic. Cycloalkyl can be independently substituted by halogen atoms, sulfonyl C1-8 alkyl groups, sulfoxide C1-8 alkyl groups, sulfonamide groups, nitro groups, cyano groups, —OC1-8 alkyl groups, —SC1-8 alkyl groups, —C1-8 alkyl groups, —C2-6 alkenyl groups, —C2-6 alkynyl groups, ketone groups, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyl groups or hydroxyl groups.
  • The term “cycloalkenyl”, as used herein, refers to a monovalent or divalent group of 3 to 8 carbon atoms derived from a saturated cycloalkyl having at least one double bond. Cycloalkenyl groups can be monocyclic or polycyclic. Cycloalkenyl groups can be independently substituted by halogen atoms, sulfonyl groups, sulfoxide groups, nitro groups, cyano groups, —OC1-6 alkyl groups, —SC1-6 alkyl groups, —C1-6 alkyl groups, —C2-6 alkenyl groups, —C2-6 alkynyl groups, ketone groups, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyl groups or hydroxyl groups.
  • The term “halogen”, as used herein, refers to an atom of chlorine, bromine, fluorine, iodine.
  • The term “alkenyl”, as used herein, refers to a monovalent or divalent hydrocarbon radical having 2 to 6 carbon atoms, derived from a saturated alkyl, having at least one double bond. One methylene (—CH2—) group, of the alkenyl can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C3-8 cycloalkyl, by a divalent heterocycle, or by a divalent aryl group. C2-6 alkenyl can be in the E or Z configuration. Alkenyl groups can be substituted by alkyl groups, as defined above or by halogen atoms.
  • The term “alkynyl”, as used herein, refers to a monovalent or divalent hydrocarbon radical having 2 to 6 carbon atoms, derived from a saturated alkyl, having at least one triple bond. One methylene (—CH2—) group, of the alkynyl can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C3-8 cycloalkyl, by a divalent heterocycle, or by a divalent aryl group. Alkynyl groups can be substituted by alkyl groups, as defined above, or by halogen atoms.
  • The term “heterocycle” as used herein, refers to a 3 to 10 membered ring, which can be aromatic or non-aromatic, saturated or unsaturated, containing at least one heteroatom selected form oxygen, nitrogen, sulfur, or combinations of at least two thereof, interrupting the carbocyclic ring structure. The heterocyclic ring can be interrupted by a C═O; the S and N heteroatoms can be oxidized. Heterocycles can be monocyclic or polycyclic. Heterocyclic ring moieties can be substituted by halogen atoms, sulfonyl groups, sulfoxide groups, nitro groups, cyano groups, —OC1-6 alkyl groups, —SC1-6 alkyl groups, —C1-8 alkyl groups, —C2-6 alkenyl groups, —C2-6 alkynyl groups, ketone groups, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyl groups or hydroxyl groups.
  • The term “aryl” as used herein, refers to an organic moiety derived from an aromatic hydrocarbon consisting of a ring containing 6 to 10 carbon atoms, by removal of one hydrogen atom. Aryl can be substituted by halogen atoms, sulfonyl C1-6 alkyl groups, sulfoxide C1-6 alkyl groups, sulfonamide groups, carboxylic acid groups, C1-6 alkyl carboxylates (ester) groups, amide groups, nitro groups, cyano groups, —OC1-6 alkyl groups, —SC1-6 alkyl groups, —C1-6 alkyl groups, —C2-6 alkenyl groups, —C2-6 alkynyl groups, ketone groups, aldehydes, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyl groups or hydroxyl groups. Aryls can be monocyclic or polycyclic.
  • The term “hydroxyl” as used herein, represents a group of formula “—OH”.
  • The term “carbonyl” as used herein, represents a group of formula “—C(O)—”.
  • The term “ketone” as used herein, represents an organic compound having a carbonyl group linked to a carbon atom such as —(CO)Rx wherein Rx can be alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • The term “amine” as used herein, represents a group of formula “—NRxRy”, wherein Rx and Ry can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • The term “carboxyl” as used herein, represents a group of formula “—C(O)O—”.
  • The term “sulfonyl” as used herein, represents a group of formula “—SO2—”.
  • The term “sulfate” as used herein, represents a group of formula “—O—S(O)2—O—”.
  • The term “sulfonate” as used herein, represents a group of the formula “—S(O)2—O—”.
  • The term “carboxylic acid” as used herein, represents a group of formula “—C(O)OH”.
  • The term “nitro” as used herein, represents a group of formula “—NO2”.
  • The term “cyano” as used herein, represents a group of formula “—CN”.
  • The term “amide” as used herein, represents a group of formula “—C(O)NRxRy” wherein Rx and Ry can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • The term “sulfonamide” as used herein, represents a group of formula “—S(O)2NRxRy” wherein Rx and Ry can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • The term “sulfoxide” as used herein, represents a group of formula “—S(O)—”.
  • The term “phosphonic acid” as used herein, represents a group of formula “—P(O)(OH)2”.
  • The term “phosphoric acid” as used herein, represents a group of formula “—OP(O)(OH)2”.
  • The term “sulphonic acid” as used herein, represents a group of formula “—S(O)2OH”.
  • The formula “H”, as used herein, represents a hydrogen atom.
  • The formula “O”, as used herein, represents an oxygen atom.
  • The formula “N”, as used herein, represents a nitrogen atom.
  • The formula “S”, as used herein, represents a sulfur atom.
  • The invention discloses compounds
    • {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H-indol-3-yl)propanoyl]amino}acetic acid; tert-butyl {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H-indol-3-yl)propanoyl]amino}acetate;
    • [(4-amino-2-{[(4-bromophenyl)carbamoyl]amino}-4-oxobutanoyl)amino]acetic acid;
    • tert-butyl [(4-amino-2-{[(4-bromophenyl)carbamoyl]amino}-4-oxobutanoyl)amino]acetate;
    • 2-{[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-2-methylpropanoic acid;
    • tert-butyl 2-{[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-2-methylpropanoate;
    • {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H-imidazol-4-yl)propanoyl]amino}acetic acid;
    • tert-butyl {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H-imidazol-4-yl)propanoyl]amino}acetate;
    • {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-(methylsulfonyl)butanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-(methylsulfonyl)butanoyl]amino}acetate;
    • {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-(methylsulfanyl)butanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-(methylsulfanyl)butanoyl]amino}acetate;
    • 2-methyl-2-{[(2S)-4-methyl-2-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}propanoic acid;
    • tert-butyl 2-methyl-2-{[(2S)-4-methyl-2-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}propanoate;
    • {[(2S)-4-methyl-2-({[4-(methylsulfonyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-4-methyl-2-({[4-(methylsulfonyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate;
    • {[(2S)-4-methyl-2-({[4-(methylsulfinyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-4-methyl-2-({[4-(methylsulfinyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate;
    • 2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-2-methylpropanoic acid;
    • tert-butyl 2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-2-methylpropanoate;
    • ({(2S)-4-methyl-2-[({4-[(trifluoromethyl)sulfanyl]phenyl}carbamoyl)amino]pentanoyl}amino)acetic acid;
    • tert-butyl ({(2S)-4-methyl-2-[({4-[(trifluoromethyl)sulfanyl]phenyl}carbamoyl)amino]pentanoyl}amino)acetate;
    • {[(2S)-4-methyl-2-({[4-(methylsulfanyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-4-methyl-2-({[4-(methylsulfanyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate;
    • {[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetic acid;
    • tert-butyl{[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetate;
    • {[(2R,3R)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methylpentanoyl]amino}acetic acid tert-butyl {[(2R,3R)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methylpentanoyl]amino}acetate;
    • {[(2S)-4-methyl-2-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-4-methyl-2-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate;
    • {[(2R)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetic acid;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-[2-(dimethylamino)-2-oxoethyl]-4-methylpentanamide;
    • [(2-{[(4-bromophenyl)carbamoyl]amino}-2-methylpropanoyl)amino]acetic acid;
    • tert-butyl [(2-{[(4-bromophenyl)carbamoyl]amino}-2-methylpropanoyl)amino]acetate;
    • [(2-{[(4-bromophenyl)carbamoyl]amino}-2-ethylbutanoyl)amino]acetic acid;
    • tert-butyl [(2-{[(4-bromophenyl)carbamoyl]amino}-2-ethylbutanoyl)amino]acetate;
    • [(2-{[(4-bromophenyl)carbamoyl]amino}-2,4-dimethylpentanoyl)amino]acetic acid;
    • tert-butyl [(2-{[(4-bromophenyl)carbamoyl]amino}-2,4-dimethylpentanoyl)amino]acetate;
    • (2S)—N-[(1S)-2-amino-2-oxo-1-phenylethyl]-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanamide;
    • (2S)-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}(phenyl)ethanoic acid;
    • tert-butyl (2S)-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}(phenyl)ethanoate;
    • (2S)—N-[(2S)-1-amino-1-oxopentan-2-yl]-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanamide;
    • (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}pentanoic acid;
    • tert-butyl (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}pentanoate;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-[(2R)-1-hydroxypropan-2-yl]-4-methylpentanamide;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2,3-dihydroxypropyl)-4-methylpentanamide;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(1,3-dihydroxypropan-2-yl)-4-methylpentanamide;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-hydroxy-2-methylpropyl)-4-methylpentanamide;
    • (2S)—N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanamide;
    • (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-3-methylbutanoic acid;
    • tert-butyl (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-3-methylbutanoate;
    • (2S)—N-[(2S)-1-amino-1-oxopropan-2-yl]-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanamide;
    • (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}propanoic acid;
    • tert-butyl (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}propanoate;
    • (2S)—N-[(2S)-1-amino-1-oxopropan-2-yl]-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanamide;
    • (2S)-2-{[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}propanoic acid;
    • tert-butyl (2S)-2-{[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}propanoate;
    • (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)-4-methylpentanamide;
    • (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methyl-N-(2-oxopropyl)pentanamide;
    • (2S)—N-(2-amino-2-oxoethyl)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanamide;
    • {[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetate;
    • (2S)—N-(2-amino-2-oxoethyl)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}pentanamide;
    • (2S)—N-(2-amino-2-oxoethyl)-2-{[(4-bromophenyl)carbamoyl]amino}pentanamide;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methyl-N-(2-oxopropyl)pentanamide;
    • (2S)—N-(2-amino-2-oxoethyl)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanamide;
    • {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetic acid;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)-4-methylpentanamide;
    • tert-butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetate;
    • {[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}pentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}pentanoyl]amino}acetate;
    • (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2-oxopropyl)pentanamide;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-oxopropyl)pentanamide;
    • propan-2-yl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}pentanoyl]amino}acetate;
    • ethyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}pentanoyl]amino}acetate;
    • methyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}pentanoyl]amino}acetate;
    • (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)pentanamide;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)pentanamide;
    • (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)-3-phenylpropanamide;
    • {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}pentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}pentanoyl]amino}acetate;
    • (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2-oxopropyl)-3-phenylpropanamide;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-oxopropyl)-3-phenylpropanamide;
    • (2S,3S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)-3-methylpentanamide;
    • (2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)-3-methylpentanamide;
    • (2S,3S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-3-methyl-N-(2-oxopropyl)pentanamide;
    • (2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methyl-N-(2-oxopropyl)pentanamide;
    • (2S,3S)—N-(2-amino-2-oxoethyl)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-3-methylpentanamide;
    • (2S,3S)—N-(2-amino-2-oxoe;thyl)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methylpentanamide;
    • {[(2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methylpentanoyl]amino}acetic acid;
    • tert-butyl {[(2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methylpentanoyl]amino}acetate;
    • {[(2S,3S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-3-methylpentanoyl]amino}acetic acid;
    • tert-butyl {[(2S,3S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-3-methylpentanoyl]amino}acetate;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)-3-phenylpropanamide;
    • 3-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-phenylpropanoyl]amino}propanoic acid;
    • tert-butyl 3-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-phenylpropanoyl]amino}propanoate;
    • {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-phenylpropanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-phenylpropanoyl]amino}acetate.
  • In another aspect the invention discloses compounds:
    • {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H-imidazol-4-yl)propanoyl]amino}acetic acid;
    • tert-butyl {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H-imidazol-4-yl)propanoyl]amino}acetate;
    • {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-(methylsulfonyl)butanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-(methylsulfonyl)butanoyl]amino}acetate;
    • {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-(methylsulfanyl)butanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-(methylsulfanyl)butanoyl]amino}acetate;
    • 2-methyl-2-{[(2S)-4-methyl-2-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}propanoic acid;
    • tert-butyl 2-methyl-2-{[(2S)-4-methyl-2-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}propanoate;
    • {[(2S)-4-methyl-2-({[4-(methylsulfonyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-4-methyl-2-({[4-(methylsulfonyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate;
    • {[(2S)-4-methyl-2-({[4-(methylsulfinyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-4-methyl-2-({[4-(methylsulfinyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate;
    • 2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-2-methylpropanoic acid;
    • tert-butyl 2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-2-methylpropanoate;
    • ({(2S)-4-methyl-2-[({4-[(trifluoromethyl)sulfanyl]phenyl}carbamoyl)amino]pentanoyl}amino)acetic acid;
    • tert-butyl ({(2S)-4-methyl-2-[({4-[(trifluoromethyl)sulfanyl]phenyl}carbamoyl)amino]pentanoyl}amino)acetate;
    • {[(2S)-4-methyl-2-({[4-(methylsulfanyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-4-methyl-2-({[4-(methylsulfanyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate;
    • {[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetic acid;
    • tert-butyl {[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetate;
    • {[(2R,3R)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methylpentanoyl]amino}acetic acid;
    • tert-butyl {[(2R,3R)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methylpentanoyl]amino}acetate;
    • {[(2S)-4-methyl-2-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-4-methyl-2-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-[2-(dimethylamino)-2-oxoethyl]-4-methylpentanamide;
    • [(2-{[(4-bromophenyl)carbamoyl]amino}-2-methylpropanoyl)amino]acetic acid;
    • tert-butyl [(2-{[(4-bromophenyl)carbamoyl]amino}-2-methylpropanoyl)amino]acetate;
    • [(2-{[(4-bromophenyl)carbamoyl]amino}-2-ethylbutanoyl)amino]acetic acid;
    • tert-butyl [(2-{[(4-bromophenyl)carbamoyl]amino}-2-ethylbutanoyl)amino]acetate;
    • [(2-{[(4-bromophenyl)carbamoyl]amino}-2,4-dimethylpentanoyl)amino]acetic acid;
    • tert-butyl [(2-{[(4-bromophenyl)carbamoyl]amino}-2,4-dimethylpentanoyl)amino]acetate;
    • (2S)—N-[(1S)-2-amino-2-oxo-1-phenylethyl]-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanamide;
    • (2S)-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}(phenyl)ethanoic acid;
    • tert-butyl (2S)-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}(phenyl)ethanoate;
    • (2S)—N-[(2S)-1-amino-1-oxopentan-2-yl]-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanamide;
    • (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}pentanoic acid;
    • tert-butyl (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}pentanoate;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-[(2R)-1-hydroxypropan-2-yl]-4-methylpentanamide;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2,3-dihydroxypropyl)-4-methylpentanamide;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(1,3-dihydroxypropan-2-yl)-4-methylpentanamide;
    • (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-hydroxy-2-methylpropyl)-4-methylpentanamide;
    • (2S)—N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanamide;
    • (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-3-methylbutanoic acid;
    • tert-butyl (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-3-methylbutanoate;
    • (2S)—N-[(2S)-1-amino-1-oxopropan-2-yl]-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanamide;
    • (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}propanoic acid;
    • tert-butyl (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}propanoate;
    • (2S)—N-[(2S)-1-amino-1-oxopropan-2-yl]-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanamide;
    • (2S)-2-{[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}propanoic acid;
    • tert-butyl (2S)-2-{[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}propanoate;
    • (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)-4-methylpentanamide;
    • (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methyl-N-(2-oxopropyl)pentanamide;
    • (2S)—N-(2-amino-2-oxoethyl)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanamide;
    • {[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetic acid;
    • tert-butyl {[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetate;
    • tert-butyl 2-{[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-2-methylpropanoate;
    • 2-{[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-2-methylpropanoic acid;
    • tert-butyl [(4-amino-2-{[(4-bromophenyl)carbamoyl]amino}-4-oxobutanoyl)amino]acetate;
    • [(4-amino-2-{[(4-bromophenyl)carbamoyl]amino}-4-oxobutanoyl)amino]acetic acid;
    • tert-butyl {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H-indol-3-yl)propanoyl]amino}acetate;
    • {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H-indol-3-yl)propanoyl]amino}acetic acid.
  • Some compounds of Formula I and of Formula II and some of their intermediates have at least one asymmetric center in their structure. This asymmetric center may be present in an R or S configuration, said R and S notation is used in correspondence with the rules described in Pure Appli. Chem. (1976), 45, 11-13.
  • The term “pharmaceutically acceptable salts” refers to salts or complexes that retain the desired biological activity of the above identified compounds and exhibit minimal or no undesired toxicological effects. The “pharmaceutically acceptable salts” according to the invention include therapeutically active, non-toxic base or acid salt forms, which the compounds of Formula I and of Formula II are able to form.
  • The acid addition salt form of a compound of Formula I and of Formula II that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an inorganic acid, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; or an organic acid such as for example, acetic acid, hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, malonic acid, fumaric acid, maleic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, citric acid, methylsulfonic acid, ethanesulfonic acid, benzenesulfonic acid, formic and the like (Handbook of Pharmaceutical Salts, P. Heinrich Stahl & Camille G. Wermuth (Eds), Verlag Helvetica Chemica Acta-Zirich, 2002, 329-345).
  • The base addition salt form of a compound of Formula I and of Formula II that occurs in its acid form can be obtained by treating the acid with an appropriate base such as an inorganic base, for example, sodium hydroxide, magnesium hydroxide, potassium hydroxide, Calcium hydroxide, ammonia and the like; or an organic base such as for example, L-Arginine, ethanolamine, betaine, benzathine, morpholine and the like. (Handbook of Pharmaceutical Salts, P. Heinrich Stahal& Camille G. Wermuth (Eds), Verlag Helvetica Chemica Acta-Zirich, 2002, 329-345).
  • Compounds of Formula I and of Formula II and their salts can be in the form of a solvate, which is included within the scope of the present invention. Such solvates include for example hydrates, alcoholates and the like.
  • With respect to the present invention reference to a compound or compounds, is intended to encompass that compound in each of its possible isomeric forms and mixtures thereof unless the particular isomeric form is referred to specifically.
  • Compounds according to the present invention may exist in different polymorphic forms. Although not explicitly indicated in the above formula, such forms are intended to be included within the scope of the present invention.
  • The compounds of the invention are indicated for use in treating or preventing conditions in which there is likely to be a component involving the N-formyl peptide receptor like-1 receptor.
  • In another embodiment, there are provided pharmaceutical compositions including at least one compound of the invention in a pharmaceutically acceptable carrier.
  • In a further embodiment of the invention, there are provided methods for treating disorders associated with modulation of the N-formyl peptide receptor like-1 receptor.
  • Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one compound of the invention.
  • Therapeutic utilities of the N-formyl peptide receptor like-1 receptor modulators are ocular inflammatory diseases including, but not limited to, wet and dry age-related macular degeneration (ARMD), uveitis, dry eye, Keratitis, allergic eye disease and conditions affecting the posterior part of the eye, such as maculopathies and retinal degeneration including non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, diabetic retinopathy (proliferative), retinopathy of prematurity (ROP), acute macular neuroretinopathy, central serous chorioretinopathy, cystoid macular edema, and diabetic macular edema; infectious keratitis, uveitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, uveitis, retinitis, and choroiditis such as acute multifocal placoid pigment epitheliopathy, Behcet's disease, birdshot retinochoroidopathy, infectious (syphilis, lyme, tuberculosis, toxoplasmosis), intermediate uveitis (pars planitis), multifocal choroiditis, multiple evanescent white dot syndrome (mewds), ocular sarcoidosis, posterior scleritis, serpiginous choroiditis, subretinal fibrosis and uveitis syndrome, Vogt-Koyanagi- and Harada syndrome; vascular diseases/exudative diseases such as retinal arterial occlusive disease, central retinal vein occlusion, cystoids macular edema, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat's disease, parafoveal telangiectasis, hemi-retinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease (CAD), frosted branch angiitis, sickle cell retinopathy and other hemoglobinopathies, angioid streaks, familial exudative vitreoretinopathy, and Eales disease; traumatic/surgical conditions such as sympathetic ophthalmia, uveitic retinal disease, retinal detachment, trauma, post surgical corneal wound healing, conditions caused by laser, conditions caused by photodynamic therapy, photocoagulation, hypoperfusion during surgery, radiation retinopathy, and bone marrow transplant retinopathy; proliferative disorders such as proliferative vitreal retinopathy and epiretinal membranes, and proliferative diabetic retinopathy; infectious disorders such as ocular histoplasmosis, ocular toxocariasis, presumed ocular histoplasmosis syndrome (POHS), endophthalmitis, toxoplasmosis, retinal diseases associated with HIV infection, choroidal disease associate with HIV infection, uveitic disease associate with HIV infection, viral retinitis, acute retinal necrosis, progressive outer retinal necrosis, fungal retinal diseases, ocular syphilis, ocular tuberculosis, diffuse unilateral subacute neuroretinitis, and myiasis; genetic disorders such as retinitis pigmentosa, systemic disorders with accosiated retinal dystrophies, congenital stationary night blindness, cone dystrophies, Stargardt's disease and fundus flavimaculatus, Best's disease, pattern dystrophy of the retinal pigmented epithelium, X-linked retinoschisis, Sorsby's fundus dystrophy, benign concentric maculopathy, Bietti's crystalline dystrophy, and pseudoxanthoma elasticum; retinal tears/holes such as retinal detachment, macular hole, and giant retinal tear; tumors such as retinal disease associated with tumors, congenital hypertrophy of the retinal pigmented epithelium, posterior uveal melanoma, choroidal hemangioma, choroidal osteoma, choroidal metastasis, combined hamartoma of the retina and retinal pigmented epithelium, retinoblastoma, vasoproliferative tumors of the ocular fundus, retinal astrocytoma, and intraocular lymphoid tumors; and miscellaneous other diseases affecting the posterior part of the eye such as punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, myopic retinal degeneration, and acute retinal pigment epitheliitis, systemic inflammatory diseases such as stroke, coronary artery disease, obstructive airway diseases, HIV-mediated retroviral infections, cardiovascular disorders including coronary artery disease, neuroinflammation, neurological disorders, pain and immunological disorders, asthma, allergic disorders, inflammation, systemic lupus erythematosus, psoriasis, CNS disorders such as Alzheimer's disease, arthritis, sepsis, inflammatory bowel disease, cachexia, angina pectoris, post-surgical corneal inflammation, blepharitis, MGD, dermal wound healing, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, viral warts, photoaging, rheumatoid arthritis and related inflammatory disorders, alopecia, glaucoma, branch vein occlusion, Best's vitelliform macular degeneration, retinitis pigmentosa, proliferative vitreoretinopathy (PVR), and any other degenerative disease of either the photoreceptors or the RPE (Perretti, Mauro et al. Pharmacology & Therapeutics 127 (2010) 175-188.) These compounds are useful for the treatment of mammals, including humans, with a range of conditions and diseases that are alleviated by the N-formyl peptide receptor like-1 receptor modulation: including, but not limited to the treatment of wet and dry age-related macular degeneration (ARMD), diabetic retinopathy (proliferative), retinopathy of prematurity (ROP), diabetic macular edema, uveitis, retinal vein occlusion, cystoids macular edema, glaucoma, branch vein occlusion, Best's vitelliform macular degeneration, retinitis pigmentosa, proliferative vitreoretinopathy (PVR), and any other degenerative disease of either the photoreceptors or the RPE.
  • In still another embodiment of the invention, there are provided methods for treating disorders associated with modulation of the FPRL-1 receptor. Such methods can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of at least one compound of the invention, or any combination thereof, or pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual isomers, enantiomers, and diastereomers thereof.
  • The present invention concerns the use of a compound of Formula I and of Formula II or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of ocular inflammatory diseases including, but not limited to, wet and dry age-related macular degeneration (ARMD), uveitis, dry eye, Keratitis, allergic eye disease and conditions affecting the posterior part of the eye, such as maculopathies and retinal degeneration including non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, diabetic retinopathy (proliferative), retinopathy of prematurity (ROP), acute macular neuroretinopathy, central serous chorioretinopathy, cystoid macular edema, and diabetic macular edema; infectious keratitis, uveitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, uveitis, retinitis, and choroiditis such as acute multifocal placoid pigment epitheliopathy, Behcet's disease, birdshot retinochoroidopathy, infectious (syphilis, lyme, tuberculosis, toxoplasmosis), intermediate uveitis (pars planitis), multifocal choroiditis, multiple evanescent white dot syndrome (mewds), ocular sarcoidosis, posterior scleritis, serpiginous choroiditis, subretinal fibrosis and uveitis syndrome, Vogt-Koyanagi- and Harada syndrome; vascular diseases/exudative diseases such as retinal arterial occlusive disease, central retinal vein occlusion, cystoids macular edema, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat's disease, parafoveal telangiectasis, hemi-retinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease (CAD), frosted branch angiitis, sickle cell retinopathy and other hemoglobinopathies, angioid streaks, familial exudative vitreoretinopathy, and Eales disease; traumatic/surgical conditions such as sympathetic ophthalmia, uveitic retinal disease, retinal detachment, trauma, post surgical corneal wound healing, conditions caused by laser, conditions caused by photodynamic therapy, photocoagulation, hypoperfusion during surgery, radiation retinopathy, and bone marrow transplant retinopathy; proliferative disorders such as proliferative vitreal retinopathy and epiretinal membranes, and proliferative diabetic retinopathy; infectious disorders such as ocular histoplasmosis, ocular toxocariasis, presumed ocular histoplasmosis syndrome (POHS), endophthalmitis, toxoplasmosis, retinal diseases associated with HIV infection, choroidal disease associate with HIV infection, uveitic disease associate with HIV infection, viral retinitis, acute retinal necrosis, progressive outer retinal necrosis, fungal retinal diseases, ocular syphilis, ocular tuberculosis, diffuse unilateral subacute neuroretinitis, and myiasis; genetic disorders such as retinitis pigmentosa, systemic disorders with accosiated retinal dystrophies, congenital stationary night blindness, cone dystrophies, Stargardt's disease and fundus flavimaculatus, Best's disease, pattern dystrophy of the retinal pigmented epithelium, X-linked retinoschisis, Sorsby's fundus dystrophy, benign concentric maculopathy, Bietti's crystalline dystrophy, and pseudoxanthoma elasticum; retinal tears/holes such as retinal detachment, macular hole, and giant retinal tear; tumors such as retinal disease associated with tumors, congenital hypertrophy of the retinal pigmented epithelium, posterior uveal melanoma, choroidal hemangioma, choroidal osteoma, choroidal metastasis, combined hamartoma of the retina and retinal pigmented epithelium, retinoblastoma, vasoproliferative tumors of the ocular fundus, retinal astrocytoma, and intraocular lymphoid tumors; and miscellaneous other diseases affecting the posterior part of the eye such as punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, myopic retinal degeneration, and acute retinal pigment epitheliitis, systemic inflammatory diseases such as stroke, coronary artery disease, obstructive airway diseases, HIV-mediated retroviral infections, cardiovascular disorders including coronary artery disease, neuroinflammation, neurological disorders, pain and immunological disorders, asthma, allergic disorders, inflammation, systemic lupus erythematosus, psoriasis, CNS disorders such as Alzheimer's disease, arthritis, sepsis, inflammatory bowel disease, cachexia, angina pectoris, post-surgical corneal inflammation, blepharitis, MGD, dermal wound healing, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, viral warts, photoaging, rheumatoid arthritis and related inflammatory disorders, alopecia, glaucoma, branch vein occlusion, Best's vitelliform macular degeneration, retinitis pigmentosa, proliferative vitreoretinopathy (PVR), and any other degenerative disease of either the photoreceptors or the RPE.
  • The actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the severity of the condition, the age and weight of the patient, the patient's general physical condition, the cause of the condition, and the route of administration.
  • The patient will be administered the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like, or other routes may be desirable or necessary, particularly if the patient suffers from nausea. Such other routes may include, without exception, transdermal, parenteral, subcutaneous, intranasal, via an implant stent, intrathecal, intravitreal, topical to the eye, back to the eye, intramuscular, intravenous, and intrarectal modes of delivery. Additionally, the formulations may be designed to delay release of the active compound over a given period of time, or to carefully control the amount of drug released at a given time during the course of therapy.
  • In another embodiment of the invention, there are provided pharmaceutical compositions including at least one compound of the invention in a pharmaceutically acceptable carrier thereof. The phrase “pharmaceutically acceptable” means the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • Pharmaceutical compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a patch, a micelle, a liposome, and the like, wherein the resulting composition contains one or more compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications. Invention compounds may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. Invention compounds are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.
  • Pharmaceutical compositions containing invention compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets containing invention compounds in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the invention compounds are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the invention compounds are mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • The pharmaceutical compositions may be in the form of a sterile injectable suspension. This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.
  • The compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions may be prepared by mixing the invention compounds with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.
  • Since individual subjects may present a wide variation in severity of symptoms and each drug has its unique therapeutic characteristics, the precise mode of administration and dosage employed for each subject is left to the discretion of the practitioner.
  • The compounds and pharmaceutical compositions described herein are useful as medicaments in mammals, including humans, for treatment of diseases and/or alleviations of conditions which are responsive to treatment by agonists or functional antagonists of the N-formyl peptide receptor like-1 (FPRL-1) receptor. Thus, in further embodiments of the invention, there are provided methods for treating a disorder associated with modulation of the N-formyl peptide receptor like-1 (FPRL-1) receptor. Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one invention compound. As used herein, the term “therapeutically effective amount” means the amount of the pharmaceutical composition that will elicit the biological or medical response of a subject in need thereof that is being sought by the researcher, veterinarian, medical doctor or other clinician. In some embodiments, the subject in need thereof is a mammal. In some embodiments, the mammal is human.
  • The present invention concerns also processes for preparing the compounds of Formula I. The compounds of formula I according to the invention can be prepared analogously to conventional methods as understood by the person skilled in the art of synthetic organic chemistry. Synthetic Scheme 1 set forth below, illustrates how the compounds according to the invention can be made.
  • Figure US20220202777A1-20220630-C00043
  • Figure US20220202777A1-20220630-C00044
  • Compounds of Formula I were prepared as depicted in Scheme 1. Compounds of Formula II were prepared as depicted in Scheme 2. In general, a t-butyl ester derivative of an amino acid is reacted with a substituted phenylisocyanate to produce a phenylurea derivative.
  • The t-butyl ester protecting group is then removed under acidic conditions to give the amino acid urea. The carboxylic acid group is then converted to an amide by treating the compound with activating reagents, such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) and Hydroxybenzotriazole (HOBt) in the presence of an amine, or by other methods known to those skilled in the art. At this stage, those skilled in the art will appreciate that many additional compounds that fall under the scope of the invention may be prepared by performing various common chemical reactions. Details of certain specific chemical transformations are provided in the examples.
  • Those skilled in the art will be able to routinely modify and/or adapt the following scheme to synthesize any compounds of the invention covered by Formula I or Formula II.
  • DETAILED DESCRIPTION OF THE INVENTION
  • It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention claimed. As used herein, the use of the singular includes the plural unless specifically stated otherwise.
  • It will be readily apparent to those skilled in the art that some of the compounds of the invention may contain one or more asymmetric centers, such that the compounds may exist in enantiomeric as well as in diastereomeric forms. Unless it is specifically noted otherwise, the scope of the present invention includes all enantiomers, diastereomers and racemic mixtures.
  • Some of the compounds of the invention may form salts with pharmaceutically acceptable acids or bases, and such pharmaceutically acceptable salts of the compounds described herein are also within the scope of the invention.
  • The present invention includes all pharmaceutically acceptable isotopically enriched compounds. Any compound of the invention may contain one or more isotopic atoms enriched or different than the natural ratio such as deuterium 2H (or D) in place of hydrogen 1H (or H) or use of 13C enriched material in place of 12C and the like. Similar substitutions can be employed for N, O and S. The use of isotopes may assist in analytical as well as therapeutic aspects of the invention. For example, use of deuterium may increase the in vivo half-life by altering the metabolism (rate) of the compounds of the invention. These compounds can be prepared in accord with the preparations described by use of isotopically enriched reagents.
  • The following examples are for illustrative purposes only and are not intended, nor should they be construed as limiting the invention in any manner. Those skilled in the art will appreciate that variations and modifications of the following examples can be made without exceeding the spirit or scope of the invention.
  • As will be evident to those skilled in the art, individual isomeric forms can be obtained by separation of mixtures thereof in conventional manner. For example, in the case of diastereoisomeric isomers, chromatographic separation may be employed.
  • Compound names were generated with ACD version 12.5. In general, characterization of the compounds is performed according to the following methods, NMR spectra are recorded on 300 or 600 MHz Varian and acquired at room temperature. Chemical shifts are given in ppm referenced either to internal TMS or to the solvent signal.
  • All the reagents, solvents, catalysts for which the synthesis is not described are purchased from chemical vendors such as Sigma Aldrich, Fluka, Bio-Blocks, Combi-blocks, TCI, VWR, Lancaster, Oakwood, Trans World Chemical, Alfa, Fisher, Maybridge, Frontier, Matrix, Ukrorgsynth, Toronto, Ryan Scientific, SiliCycle, Anaspec, Syn Chem, Chem-Impex, MIC-scientific, Ltd; however some known intermediates, were prepared according to published procedures.
  • Usually the compounds of the invention were purified by medium pressure liquid chromatography, unless noted otherwise.
  • The following abbreviations are used in the examples:
  • Et3N triethylamine
    CH2Cl2 dichloromethane
    CDCl3 deuterated chloroform
    MeOH methanol
    CD3OD deuterated methanol
    Na2SO4 sodium sulfate
    DMF N,N dimethylformamide
    EDCI 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
  • HOBt Hydroxybenzotriazole
  • THF tetrahydrofuran
    ClCO2Et ethylchloroformate
    NH3 ammonia
  • The following synthetic schemes illustrate how compounds according to the invention can be made. Those skilled in the art will be routinely able to modify and/or adapt the following schemes to synthesize any compound of the invention covered by Formula II.
  • Example 1 Intermediate 1 tert-Butyl (2S)-2-{[(4-Bromophenyl)carbamoyl]amino}-3-phenylpropanoate
  • Figure US20220202777A1-20220630-C00045
  • To a solution of L-phenyl-alanine tert-butyl ester hydrochloride (100 mg, 0.41 mmol) and 6 mL of methylene chloride at 25° C. was added 4-bromo-phenyl isocyanate (81 mg, 0.41 mmol) and triethylamine (62 mg, 0.62 mmol). The resulting mixture was stirred at 25° C. for 30 minutes. The mixture was concentrated and the residue was purified by medium pressure liquid chromatography on silica gel using ethyl acetate:hexane (20:80) to yield Intermediate 1, as a white solid.
  • 1H NMR (CDCl3, 300 MHz) δ: 7.20-7.35 (m, 5H), 7.13-7.20 (m, 2H), 7.01-7.10 (m, 2H), 6.79 (br. s., NH), 5.52 (br. s., NH), 4.70 (t, J=6.2 Hz, 1H), 2.91 (ddd, J=19.0 Hz, J=6.0 Hz, 2H), 1.47 (in, 9H).
  • Intermediates 2, 3 and 4 were prepared from the corresponding amino acid in a similar manner to the procedure described in Example 1 for Intermediate 1, starting with the appropriate amino acid. The results are described below in Table 1.
  • TABLE 1
    Interm. IUPAC name
    No. Structure 1H NMR δ (ppm)
    2 tert-Butyl (2S,3S)-2-{[(4-bromo 1H NMR (CDCl3, 300 MHz) δ: 7.29-
    phenyl)carbamoyl]amino}-3- 7.39 (m, 2H), 7.10-7.22 (m, 2H),
    methylpentanoate  
    Figure US20220202777A1-20220630-C00046
    6.83 (br. s., 1H), 4.44 (d, J = 4.4 Hz, 1H), 1.81-1.99 (m, 1H), 1.36-1.46 (m, 1H), 1.08-1.31 (m, 1H), 0.86- 1.02 (m, 6H).
    3 tert-Butyl (2S)-2-{[(4-bromophenyl) 1H NMR (CDCl3, 300 MHz) δ: 7.26-
    carbamoyl]amino}-pentanoate  
    Figure US20220202777A1-20220630-C00047
    7.36 (m, 2H), 7.09-7.18 (m, 2H), 6.95 (br. s., NH), 4.40-4.50 (m, 1H), 1.73-1.89 (m, 1H), 1.52-1.72 (m, 1H), 1.25-1.46 (m, 2H), 0.95 (t, 2H).
    4 tert-butyl (2S)-2-{[(4-bromo phenyl) 1H NMR (CDCl3, 300 MHz) δ: 7.20-
    carbamoyl]amino}-4- 7.33 (m, 2H), 7.04-7.15 (m, 2H),
    methylpentanoate  
    Figure US20220202777A1-20220630-C00048
    4.44 (dd, J = 9.1, 5.3 Hz, 1H), 1.74 (dd, J = 12.9, 6.4 Hz, 1H), 1.54-1.68 (m, 1H), 1.50 (s, 9H), 1.40-1.47 (m, 1H), 0.97 (d, J = 3.5 Hz, 3H), 0.95 (d, 3H).
  • Example 2 Intermediate 5 (2S)-2-{[(4-Bromophenyl)carbamoyl]amino}-3-phenylpropanoic Acid
  • Figure US20220202777A1-20220630-C00049
  • A solution of Intermediate 1 (60 mg, 0.15 mmol) and 0.5 mL of formic acid was stirred at 25° C. for 3 hours. The resulting mixture was quenched with water (1 mL) then extracted with ethyl acetate. The organic layer was washed with water, brine, dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was rinsed 4 times with methylene chloride:hexane (1:1) to yield Intermediate 5 as a white solid.
  • 1H NMR (acetone-d6, 300 MHz) δ: 8.29 (s, NH), 7.40-7.50 (m, 2H), 7.32-7.40 (m, 2H), 7.18-7.31 (m, 5H), 5.98 (d, J=7.9 Hz, NH), 4.67 (m, 1H), 3.02 (ddd, J=19.0 Hz, J=6.0 Hz, 2H).
  • Intermediates 6, 7 and 8 and Compounds 1 through 6 were prepared from the corresponding urea derivative in a similar manner to the procedure described in Example 2 for Intermediate 5. The results are described below in Table 2.
  • TABLE 2
    Interm. IUPAC name
    No. Structure 1H NMR δ (ppm)
    6 (2S,3S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ: 8.24
    carbamoyl]amino}-3- (br. s., 1H), 7.44-7.53 (m, 2H), 7.32-
    methylpentanoic acid 7.42 (m, 2H), 6.08 (d, J = 8.8 Hz, 1H),
    Figure US20220202777A1-20220630-C00050
    4.44 (dd, J = 8.6, 4.8 Hz, 1H), 1.86-2.00 (m, J = 9.1, 6.9, 4.6, 4.6 Hz, 1H), 1.43- 1.61 (m, 1H), 1.15-1.33 (m, 1H), 0.88- 1.04 (m, 6H).
    7 (2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ: 8.20
    carbamoyl]amino}-pentanoic (s, NH), 7.43-7.52 (m, 2H), 7.33-7.41
    acid (m, 2H), 6.08 (d, J = 9.1 Hz, NH), 4.38-
    Figure US20220202777A1-20220630-C00051
    4.50 (m, 1H), 1.77-1.92 (m, 1H), 1.61- 1.76 (m, 1H), 1.36-1.53 (m, 2H), 0.89- 1.00 (m, 3H).
    8 (2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ: 8.17 (s,
    carbamoyl]amino}-4- NH), 7.43-7.51 (m, 2H), 7.35-7.41 (m,
    methylpentanoic acid 2H), 6.04 (d, J = 9.1 Hz, NH), 4.42-4.53
    Figure US20220202777A1-20220630-C00052
    (m, 1H), 1.73-1.88 (m, 1H), 1.53-1.73 (m, 2H), 0.97 (d, J = 2.1 Hz, 3H), 0.95 (d, 3H).
    Comp. IUPAC name
    No. Structure 1H NMR δ (ppm)
    1 {[(2S)-2-{[(4- 1H NMR (acetone-d6, 300 MHz) δ: 8.26 (s,
    bromophenyl)carbamoyl]amino}- NH), 7.71 (br. s., NH), 7.32-7.46 (m,
    3-phenylpropanoyl] 4H), 7.13-7.31 (m, 5H), 6.03 (d, J = 8.5
    amino}acetic Hz, NH), 4.71 (td, J = 7.7, 5.4 Hz, 1H),
    acid 3.98 (d, J = 5.9 Hz, 2H), 3.14-3.26 (m,
    Figure US20220202777A1-20220630-C00053
    1H), 3.01 (dd, 1H).
    2 3-{[(2S)-2-{[(4- 1H NMR (acetone-d6, 300 MHz) δ: 8.27 (s,
    bromophenyl)carbamoyl] NH), 7.44 (s, NH), 7.33-7.43 (m, 4H),
    amino}-3- 7.15-7.30 (m, 5H), 6.03 (d, J = 7.9 Hz,
    phenylpropanoyl]amino} NH), 4.53-4.65 (m, 1H), 3.34-3.51 (m,
    propanoic acid 2H), 2.93-3.15 (m, 2H), 2.47 (td, 2H).
    Figure US20220202777A1-20220630-C00054
    3 {[(2S,3S)-2-{[(4-bromo-2- 1H NMR (acetone-d6, 300 MHz) δ: 8.28 (t,
    fluorophenyl)carbamoyl] J = 8.9 Hz, 1H), 8.16 (br. s., NH), 7.67 (br.
    amino}-3- s., NH), 7.34 (dd, J = 11.0, 2.2 Hz, 1H),
    methylpentanoyl]amino}acetic 7.23-7.30 (m, 1H), 6.57 (d, J = 9.4 Hz,
    acid NH), 4.37 (dd, J = 8.6, 5.7 Hz, 1H), 3.89-
    Figure US20220202777A1-20220630-C00055
    4.08 (m, 2H), 1.86-1.98 (m, 1H), 1.53- 1.67 (m, 1H), 1.10-1.27 (m, 1H), 0.98 (d, J = 6.7 Hz, 3H), 0.85-0.94 (m, 3H).
    4 {[(2S,3S)-2-{[(4- 1H NMR (acetone-d6, 300 MHz) δ: 8.27 (s,
    bromophenyl)carbamoyl] NH), 7.66 (br. s., NH), 7.42-7.51 (m,
    amino}-3- 2H), 7.32-7.41 (m, 2H), 6.08 (d, J = 8.2
    methylpentanoyl]amino} Hz, NH), 4.34 (dd, J = 8.6, 5.7 Hz, 1H),
    acetic acid 3.88-4.09 (m, 2H), 1.81-1.96 (m, 1H),
    Figure US20220202777A1-20220630-C00056
    1.49-1.67 (m, 1H), 1.06-1.27 (m, 1H), 0.97 (d, J = 6.7 Hz, 3H), 0.86-0.93 (m, 3H).
    5 {[(2S)-2-{[(4- 1H NMR (acetone-d6, 300 MHz) δ: 8.25 (s,
    bromophenyl)carbamoyl]amino} NH), 7.67 (br. s., NH), 7.41-7.51 (m,
    pentanoyl]amino}acetic 2H), 7.34-7.41 (m, 2H), 6.13 (d, J = 7.9
    acid Hz, NH), 4.42 (td, J = 7.7, 5.4 Hz, 1H),
    Figure US20220202777A1-20220630-C00057
    3.89-4.08 (m, 2H), 1.73-1.89 (m, 1H), 1.54-1.69 (m, 1H), 1.34-1.51 (m, 2H), 0.91 (t J = 7.3 Hz, 3H).
    6 {[(2S)-2-{[(4- 1H NMR (acetone-d6, 300 MHz) δ: 8.19 (s,
    bromophenyl)carbamoyl] NH), 7.70 (br. s., NH), 7.42-7.51 (m,
    amino}-4- 2H), 7.33-7.41 (m, 2H), 6.07 (d, J = 7.6
    methylpentanoyl]amino} Hz, NH), 4.46 (ddd, J = 9.6, 8.3, 5.0 Hz,
    acetic acid 1H), 3.87-4.07 (m, 2H), 1.72-1.86 (m,
    Figure US20220202777A1-20220630-C00058
    1H), 1.61-1.72 (m, 1H), 1.46-1.59 (m, 1H), 0.95 (s, 3H), 0.93 (s, 3H).
  • Example 3 Compound 7 tert-Butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-phenylpropanoyl]amino}acetate
  • Figure US20220202777A1-20220630-C00059
  • To a solution of Intermediate 5 (80 mg, 0.22 mmol) and 2 mL of anhydrous DMF at 25° C. was added EDCI (64 mg, 0.33 mmol), HOBt (45 mg, 0.33 mmol), glycine tert-butyl ester (44 mg, 0.33 mmol) and N-methylmorpholine (44 mg, 0.44 mmol). The resulting mixture was stirred at 25° C. for 12 hours. The mixture was quenched with water (1 mL), and the product was extracted with ethyl acetate (20 mL). The layers were separated, and the organic layer was washed with water, brine, dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The resulting product was purified by medium pressure liquid chromatography on silica gel using ethyl acetate:hexane (40:60) to yield Compound 7 as a white solid.
  • 1H NMR (CDCl3, 300 MHz) δ: 7.18-7.35 (m, 7H), 7.03 (d, J=8.5 Hz, 2H), 6.85 (br. s., 1H), 4.69 (t, J=7.5 Hz, 1H), 3.74-3.96 (min, 2H), 2.98-3.19 (m, 2H), 1.42 (s, 9H).
  • Compounds 8 through 27 and Intermediate 9 were prepared from the corresponding urea derivative in a similar manner to the procedure described in Example 3 for Compound 7. The results are described below in Table 3.
  • TABLE 3
    Comp. IUPAC name
    No. Structure 1H NMR δ (ppm)
    8 tert-butyl 3-{[(2S)-2-{[(4- 1H NMR (CDCl3, 300 MHz) δ: 7.18-
    bromophenyl)carbamoyl]amino}- 7.35 (m, 7H), 7.08-7.17 (m, 2H),
    3-phenylpropanoyl] 4.54-4.64 (m, 1H), 3.28-3.52 (m,
    amino}propanoate 2H), 2.94-3.17 (m, 2H), 2.18-2.40
    Figure US20220202777A1-20220630-C00060
    (m, 2H), 1.41 (s, 9H).
    9 (2S)-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.30-
    carbamoyl]amino}-N-(2- 7.37 (m, 2H), 7.17-7.30 (m, 7H),
    hydroxyethyl)-3-phenylpropanamide 4.50 (dd, J = 7.8, 6.3 Hz, 1H), 3.44-
    Figure US20220202777A1-20220630-C00061
    3.59 (m, 2H), 3.23-3.30 (m, 2H), 3.05-3.15 (m, 1H), 2.90-3.01 (m, 1H).
    10 tert-butyl {[(2S,3S)-2-{[(4-bromo-2- 1H NMR (CDCl3, 300 MHz) δ: 7.92-
    fluorophenyl) carbamoyl]amino}-3- 7.99 (t, J = 8.9 Hz, 1H), 7.40 (br. s.,
    methylpentanoyl]amino}acetate NH), 7.07-7.16 (m, 2H), 6.67 (s,
    Figure US20220202777A1-20220630-C00062
    NH), 6.54 (br. s., NH), 4.21-4.27 (m, 1H), 4.05-4.15 (m, 1H), 3.83- 3.92 (m, 1H), 1.79-1.88 (m, 1H), 1.57-1.64 (m, 1H), 1.47 (s, 9H), 1.19-1.24 (m, 1H), 1.00 (d, J = 6.7 Hz, 3H), 0.92 (t, 3H).
    11 tert-butyl {[(2S,3S)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 8.55
    bromophenyl) carbamoyl]amino}-3- (s, NH), 8.36 (br. s., NH), 7.33-7.40
    methylpentanoyl]amino}acetate (m, 2H), 7.26-7.33 (m, 2H), 6.28
    Figure US20220202777A1-20220630-C00063
    (d, J = 8.5 Hz, NH), 4.20 (dd, J = 8.6, 6.3 Hz, 1H), 3.72-3.97 (m, 2H), 1.80-1.94 (m, 1H), 1.56-1.70 (m, 1H), 1.45 (s, 9H), 1.13-1.31 (m, 1H), 1.01 (d, J = 6.7 Hz, 3H), 0.92- 0.98 (m, 3H).
    12 (2S,3S)-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.34-
    carbamoyl]amino}-3-methyl-N-(2- 7.41 (m, 2H), 7.26-7.34 (m, 2H),
    oxopropyl)pentanamide 4.22 (d, J = 6.2 Hz, 1H), 4.05 (d, J =
    Figure US20220202777A1-20220630-C00064
    8.2 Hz, 2H), 2.14 (s, 3H), 1.80-1.94 (m, 1H), 1.53-1.68 (m, 1H), 1.14- 1.26 (m, 1H), 0.81-1.07 (m, 6H).
    13 (2S,3S)-2-{[(4-bromo-2-fluorophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.99
    carbamoyl]amino}-3-methyl-N-(2- (t, J = 8.8 Hz, 1H), 7.31 (dd, J =
    oxopropyl)pentanamide 10.7, 2.2 Hz, 1H), 7.16-7.27 (m,
    Figure US20220202777A1-20220630-C00065
    1H), 4.22 (d, J = 5.9 Hz, 1H), 3.94- 4.14 (m, 2H), 2.14 (s, 3H), 1.84- 1.96 (m, 1H), 1.52-1.67 (m, 1H), 1.14-1.32 (m, 1H), 1.01 (d, J = 7.0 Hz, 3H), 0.92-0.98 (m, 3H).
    14 (2S,3S)-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ:
    carbamoyl]amino}-N-(2- 7.33-7.42 (m, 2H), 7.26-7.33 (m,
    hydroxyethyl)-3-methylpentanamide 2H), 4.12 (d, J = 6.4 Hz, 1H), 3.55-
    Figure US20220202777A1-20220630-C00066
    3.65 (m, 2H), 3.32-3.37 (m, 1H), 1.76-1.91 (m, 1H), 1.48-1.63 (m, 1H), 1.09-1.31 (m, 2H), 0.90-0.99 (m, 6H).
    15 (2S,3S)-2-{[(4-bromo-2-fluorophenyl) 1H NMR (CD3OD, 300 MHz) δ:
    carbamoyl]amino}-N-(2- 7.99 (t, J = 8.6 Hz, 1H), 7.31 (dd, J =
    hydroxyethyl)-3-methylpentanamide 10.8, 2.3 Hz, 1H), 7.18-7.27 (m,
    Figure US20220202777A1-20220630-C00067
    1H), 4.13 (d, J = 6.4 Hz, 1H), 3.56- 3.65 (m, 2H), 3.31-3.37 (m, 1H), 1.77-1.89 (m, 1H), 1.50-1.61 (m, 1H), 1.10-1.26 (m, 1H), 0.88-1.01 (m, 6H).
    16 (2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}-N-(2-oxopropyl)-3- 8.23 (s, NH), 7.59 (br. s., NH), 7.32-
    phenylpropanamide 7.47 (m, 4H), 7.15-7.29 (m, 5H),
    Figure US20220202777A1-20220630-C00068
    6.01 (d, J = 8.2 Hz, NH), 4.70 (td, J = 7.7, 5.7 Hz, 1H), 4.05 (d, J = 5.3 Hz, 2H), 3.12-3.24 (m, 1H), 2.95- 3.06 (m, 1H), 2.10 (s, 3H).
    17 (2S)-2-{[(4-bromo-2-fluorophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}-N-(2-oxopropyl)-3- 8.22 (t, J = 8.9 Hz, 1H), 8.12 (br. s.,
    phenylpropanamide NH), 7.61 (br. s., NH), 7.32 (dd, J =
    Figure US20220202777A1-20220630-C00069
    11.0, 2.2 Hz, 1H), 7.15-7.29 (m, 6H), 6.51 (d, J = 7.3 Hz, NH), 4.72 (td, J = 7.9, 5.6 Hz, 1H), 4.05 (dd, J = 5.6, 1.2 Hz, 2H), 3.14-3.24 (m, 1H), 2.95-3.05 (m, 1H), 2.10 (s, 3H).
    18 tert-butyl {[(2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}-pentanoyl]amino} 8.20 (s, NH), 7.60 (br. s., NH), 7.42-
    acetate 7.51 (m, 2H), 7.32-7.41 (m, 2H),
    Figure US20220202777A1-20220630-C00070
    6.07 (d, J = 7.6 Hz, NH), 4.41 (td, J = 7.9, 5.3 Hz, 1H), 3.75-3.99 (m, 2H), 1.73-1.89 (m, 1H), 1.53-1.70 (m, 1H), 1.43 (s, 9H), 1.37-1.48 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H).
    19 (2S)-2-{[(4-bromo-2-fluorophenyl) 1H NMR (CD3OD, 300 MHz) δ:
    carbamoyl]amino}-N-(2- 7.91 (t, J = 8.6 Hz, 1H), 7.17-7.34
    hydroxyethyl)-3-phenylpropanamide (m, 7H), 4.50 (dd, J = 8.2, 6.2 Hz,
    Figure US20220202777A1-20220630-C00071
    1H), 3.44-3.59 (m, 2H), 3.23-3.27 (m, 2H), 3.05-3.17 (m, 1H), 2.87- 2.99 (m, 1H).
    20 (2S)-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    carbamoyl]amino}-N-(2- 7.41 (m, 2H), 7.25-7.33 (m, 2H),
    hydroxyethyl)pentanamide 4.23 (dd, J = 8.2, 5.6 Hz, 1H), 3.56-
    Figure US20220202777A1-20220630-C00072
    3.63 (m, 2H), 1.69-1.84 (m, 1H), 1.54-1.68 (m, 1H), 1.29-1.51 (m, 2H), 0.91-1.02 (m, 3H).
    21 (2S)-2-{[(4-bromo-2-fluorophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.97
    carbamoyl]amino}-N-(2- (t, J = 8.6 Hz, 1H), 7.31 (dd, J =
    hydroxyethyl) pentanamide 10.7, 2.2 Hz, 1H), 7.19-7.27 (m,
    Figure US20220202777A1-20220630-C00073
    1H), 4.23 (dd, J = 8.1, 5.4 Hz, 1H), 3.56-3.66 (m, 2H), 1.68-1.83 (m, 1H), 1.54-1.68 (m, 1H), 1.34-1.51 (m, 2H), 0.91-1.03 (m, 3H).
    22 methyl {[(2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}- 8.19 (s, NH), 7.71 (br. s., NH), 7.42-
    pentanoyl]amino}acetate 7.52 (m, 2H), 7.31-7.42 (m, 2H),
    Figure US20220202777A1-20220630-C00074
    6.07 (d, J = 8.2 Hz, NH), 4.34-4.47 (m, 1H), 3.86-4.10 (m, 2H), 3.66 (s, 3H), 1.73-1.87 (m, 1H), 1.55-1.71 (m, 1H), 1.35-1.51 (m, 2H), 0.92 (t, 3H).
    23 ethyl {[(2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}- 8.19 (s, NH), 7.69 (br. s., NH), 7.42-
    pentanoyl]amino}acetate 7.50 (m, 2H), 7.32-7.40 (m, 2H),
    Figure US20220202777A1-20220630-C00075
    6.07 (d, J = 8.2 Hz, NH), 4.42 (td, J = 7.9, 5.6 Hz, 1H), 4.13 (q, J = 7.2 Hz, 2H), 3.85-4.06 (m, 2H), 1.73- 1.88 (m, 1H), 1.55-1.69 (m, 1H), 1.34-1.51 (m, 2H), 1.20 (t, J = 7.3, 3H), 0.92 (t, J = 7.3, 3H).
    24 isopropyl {[(2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}-pentanoyl]amino} 8.20 (s, NH), 7.67 (br. s., NH), 7.43-
    acetate 7.51 (m, 2H), 7.33-7.42 (m, 2H),
    Figure US20220202777A1-20220630-C00076
    6.07 (d, J = 9.7 Hz, NH), 4.97 (dt, J = 12.5, 6.2 Hz, 1H), 4.41 (td, J = 7.8, 5.4 Hz, 1H), 3.82-4.04 (m, 2H), 1.73-1.89 (m, 1H), 1.55-1.70 (m, 1H), 1.34-1.50 (m, 2H), 1.22 (s, 3H), 1.20 (s, 3H), 0.92 (t, J = 7.3, 3H).
    25 tert-butyl {[(2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}-4- 8.16 (s, NH), 7.62 (br. s., NH), 7.42-
    methylpentanoyl]amino}acetate 7.49 (m, 2H), 7.33-7.40 (m, 2H),
    Figure US20220202777A1-20220630-C00077
    6.03 (d, J = 8.8 Hz, NH), 4.40-4.51 (m, 1H), 3.76-3.95 (m, 2H), 1.72- 1.84 (m, 1H), 1.60-1.73 (m, 1H), 1.45-1.58 (m, 1H), 0.95 (s, 3H), 0.93 (s, 3H).
    26 (2S)-2-{[(4-bromophenyl) 1H NMR (CD3 OD, 300 MHz) δ:
    carbamoyl]amino}-N-(2- 7.34-7.41 (m, 2H), 7.26-7.33 (m,
    hydroxyethyl)-4- 2H), 4.24-4.33 (m, 1H), 3.55-3.64
    methylpentanamide (m, 2H), 3.32-3.35 (m, 2H), 1.64-
    Figure US20220202777A1-20220630-C00078
    1.79 (m, 1H), 1.48-1.62 (m, 2H), 0.98 (d, J = 4.1 Hz, 3H), 0.96 (d, J = 3.8 Hz, 3H).
    27 (2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}-4-methyl-N-(2- 8.17 (s, NH), 7.61 (br. s., NH), 7.42-
    oxopropyl)pentanamide 7.50 (m, 2H), 7.32-7.42 (m, 2H),
    Figure US20220202777A1-20220630-C00079
    6.06 (d, J = 8.5 Hz, NH), 4.45 (ddd, J = 9.7, 8.1, 5.0 Hz, 1H), 4.04 (d, J = 5.6 Hz, 2H), 2.12 (s, 3H), 1.72-1.84 (m, 1H), 1.60-1.72 (m, 1H), 1.45- 1.58 (m, 1H), 0.95 (s, 3H), 0.93 (s, 3H).
    Interm. IUPAC name
    No. Structure 1H NMR δ (ppm)
    9 (2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}-N- 10.27 (br. s., OH), 8.18 (br. s., NH),
    hydroxypentanamide 8.03 (s, NH), 7.42-7.50 (m, 2H),
    Figure US20220202777A1-20220630-C00080
    7.32-7.41 (m, 2H), 6.11 (d, J = 9.1 Hz, NH), 4.23-4.34 (m, 1H), 1.52- 1.80 (m, 2H), 1.27-1.49 (m, 2H), 0.87-0.95 (t, J = 7.3 Hz, 3H).
  • Example 4 Compound 28 (2S,3S)—N-(2-amino-2-oxoethyl)-2-{[(4-bromophenyl) carbamoyl]amino}-3-methylpentanamide
  • Figure US20220202777A1-20220630-C00081
  • To a solution of Compound 11 (50 mg, 0.13 mmol) and 5 mL of anhydrous tetrahydrofuran under argon at −78° C. was added triethylamine (24 mg, 0.17 mmol) and ethyl chloroformate (17 mg, 0.16 mmol). The mixture was stirred at −78° C. for 30 minutes, and then ammonia gas was bubbled into reaction flask for 1 minute. The resulting mixture was stirred at 25° C. for 2 hours. The reaction was quenched with water (1 mL), and the residue was extracted with ethyl acetate (20 mL). The layers were separated, and the organic layer was washed with water, brine, dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The resulting product was purified by medium pressure chromatography on silica gel using an eluent of methanol:dichloromethane (10:90) to yield to yield Compound 28 as a white solid.
  • 1H NMR (CD3OD, 300 MHz) δ: 7.33-7.40 (i, 2H), 7.26-7.33 (8, 2H), 4.05 (d, J=6.7 Hz, 1H), 3.85 (q, J=17.0 Hz, 2H), 1.78-1.91 (m, 1H), 1.54-1.69 (n, TH), 1.16-1.33 (n, TH), 0.99 (d, J=6.7 Hz, 3H), 0.92-0.98 (n, 3H).
  • Compounds 29 through 85 as well as Intermediates 10 through 35 were prepared from the corresponding acid derivative in a similar manner to the procedure described in Example 4 for Compound 28.
  • TABLE 4
    Comp. IUPAC name
    No. Structure 1H NMR δ (ppm)
    29 (2S,3S)-N-(2-amino-2-oxoethyl)-2- 1H NMR (CD3OD, 300 MHz) δ: 8.00
    {[(4-bromo-2-fluorophenyl) (t, J = 8.6 Hz, 1H), 7.32 (dd, J = 10.7,
    carbamoyl]amino}-3- 2.2 Hz, 1H), 7.18-7.26 (m, 1H), 4.05
    methylpentanamide (d, J = 6.4 Hz, 1H), 3.74-3.95 (m, 2H),
    Figure US20220202777A1-20220630-C00082
    1.80-1.91 (m, 1H), 1.51-1.69 (m, 1H), 1.18-1.32 (m, 1H), 1.00 (d, J = 7.0 Hz, 3H), 0.92-0.98 (m, 3H).
    30 (2S)-N-(2-amino-2-oxoethyl)-2- 1H NMR (acetone-d6, 300 MHz) δ: 8.27
    {[(4-bromophenyl) (s, NH), 7.70 (br. s., NH), 7.41-7.48
    carbamoyl]amino}-pentanamide (m, 2H), 7.33-7.41 (m, 2H), 7.02 (s,
    Figure US20220202777A1-20220630-C00083
    NH), 6.30 (s, NH), 6.22 (d, J = 5.3 Hz, NH), 4.22-4.32 (m, 1H), 3.72-3.91 (m, 2H), 1.73-1.88 (m, 1H), 1.56- 1.71 (m, 1H), 1.37-1.53 (m, 2H), 0.88- 0.97 (m, 3H).
    31 (2S)-N-(2-amino-2-oxoethyl)-2- 1H NMR (acetone-d6, 300 MHz) δ: 8.23
    {[(4-bromo-2-fluorophenyl] (t, J = 8.8 Hz, 1H), 8.13 (br. s., NH),
    carbamoyl}amino)pentanamide 7.72 (s, NH), 7.35 (dd, J = 10.8, 2.3 Hz,
    Figure US20220202777A1-20220630-C00084
    1H), 7.26 (dt, J = 8.9, 1.9 Hz, 1H), 7.00 (s, NH), 6.66 (d, J = 6.7 Hz, NH), 6.34 (s, NH), 4.29 (dd, J = 12.2, 8.1 Hz, 1H), 3.82 (dd, J = 5.9, 1.8 Hz, 2H), 1.75- 1.90 (m, 1H), 1.58-1.73 (m, 1H), 1.37- 1.53 (m, 2H), 0.89-0.98 (m, 3H).
    32 (2S)-N-(2-amino-2-oxoethyl)-2- 1H NMR (acetone-d6, 300 MHz) δ: 8.20
    {[(4-bromophenyl) (s, NH), 7.77 (br. s., NH), 7.40-7.47
    carbamoyl]amino}-4- (m, 2H), 7.32-7.39 (m, 2H), 7.04 (br.
    methylpentanamide s., NH), 6.38 (br. s., NH), 6.18 (d, J =
    Figure US20220202777A1-20220630-C00085
    7.3 Hz, NH), 4.31 (ddd, J = 9.4, 7.0, 5.3 Hz, 1H), 3.71-3.93 (m, 2H), 1.69- 1.85 (m, 1H), 1.49-1.69 (m, 2H), 0.96 (d, J = 3.2 Hz, 3H), 0.93 (d, J = 3.2 Hz, 3H).
    33 tert-butyl {[(2S)-2-{[(4-bromo-2- 1H NMR (CDCl3, 300 MHz) δ: 7.89 (t,
    fluorophenyl) carbamoyl] amino}- J = 8.8 Hz, 1H), 7.55 (br. s., NH), 7.07
    4-methylpentanoyl] amino}acetate (dd, J = 10.7, 2.2 Hz, 1H), 6.95-7.04
    Figure US20220202777A1-20220630-C00086
    (m, 1H), 6.84 (br. s., NH), 4.43 (br. s., NH), 4.00-4.16 (m, 1H), 3.81-3.92 (m, 1H), 1.69-1.88 (m, 1H), 1.56- 1.70 (m, 2H), 1.47 (s, 9H), 0.97 (d, J = 4.7 Hz, 3H), 0.95 (d, 3H).
    34 {[(2S)-2-{[(4-bromo-2- 1H NMR (acetone-d6, 300 MHz) δ: 8.27
    fluorophenyl) carbamoyl]amino}-4- (t, J = 8.8 Hz, 1H), 8.07 (br. s., NH),
    methylpentanoyl]amino}acetic acid 7.71 (br. s., NH), 7.34 (dd, J = 10.8, 2.1
    Figure US20220202777A1-20220630-C00087
    Hz, 1H), 7.27 (dt, J = 8.8, 1.8 Hz, 1H), 6.54 (d, J = 8.8 Hz, NH), 4.42-4.53 (m, 1H), 3.93-4.01 (m, 2H), 1.72- 1.86 (m, 1H), 1.63-1.74 (m, 1H), 1.46- 1.60 (m, 1H), 0.96 (s, 3H), 0.93 (s, 3H).
    35 (2S)-2-{[(4-bromo-2-fluorophenyl) 1H NMR (acetone-d6, 300 MHz) δ: 8.30
    carbamoyl]amino}-4-methyl-N-(2- (t, J = 8.8 Hz, 1H), 8.06 (br. s., NH),
    oxopropyl)pentanamide 7.62 (br. s., NH), 7.31-7.38 (m, 2H),
    Figure US20220202777A1-20220630-C00088
    7.24-7.30 (m, 2H), 6.52 (d, J = 8.2 Hz, NH), 4.39-4.53 (m, 1H), 4.04 (d, J = 5.6 Hz, 2H), 2.10-2.15 (m, 3H), 1.70- 1.86 (m, 1H), 1.61-1.71 (m, 1H), 1.47- 1.62 (m, 1H), 0.96 (s, 3H), 0.93 (s, 3H).
    36 (2S)-2-{[(4-bromo-2-fluorophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.97 (t,
    carbamoyl]amino}-N-(2- J = 8.8 Hz, 1H), 7.31 (dd, J = 10.8, 2.3
    hydroxyethyl)-4- Hz, 1H), 7.18-7.27 (m, 1H), 4.28 (dd,
    methylpentanamide J = 9.2, 5.4 Hz, 1H), 3.56-3.64 (m,
    Figure US20220202777A1-20220630-C00089
    2H), 3.32-3.37 (m, 2H), 1.64-1.80 (m, 1H), 1.50-1.62 (m, 2H), 0.98 (d, J = 4.4 Hz, 3H), 0.96 (d, 3H).
    37 (2S)-N-(2-amino-2-oxoethyl)-2-{[(4- 1H NMR (acetone-d6, 300 MHz) δ: 8.22
    bromo-2-fluorophenyl) (t, J = 8.8 Hz, 1H), 8.09 (br. s., NH),
    carbamoyl]amino}-4- 7.77 (br. s., NH), 7.34 (dd, J = 11.0, 2.2
    methylpentanamide Hz, 1H), 7.25 (dt, J = 8.9, 1.7 Hz, 1H),
    Figure US20220202777A1-20220630-C00090
    6.99 (br. s., NH), 6.62 (d, J = 7.0 Hz, NH), 6.37 (br. s., NH), 4.33 (ddd, J = 9.6, 7.0, 5.1 Hz, 1H), 3.72-3.92 (m, 2H), 1.68-1.86 (m, 1H), 1.49-1.70 (m, 2H), 0.96 (d, J = 3.5 Hz, 3H), 0.94 (d, 3H).
    38 tert-butyl (2S)-2-{[(2S)-2-{[(4- 1H NMR (CDCl3, 300 MHz) δ: 7.90 (t,
    bromo-2-fluorophenyl) J = 8.8 Hz, 1H), 7.45 (br. s., NH), 7.02-
    carbamoyl]amino}-4- 7.15 (m, 2H), 6.92 (s, NH), 6.61 (br.
    methylpentanoyl]amino} s., NH), 4.37-4.54 (m, 2H), 1.79 (dt,
    propanoate J = 13.2, 6.9 Hz, 1H), 1.56-1.69 (m,
    Figure US20220202777A1-20220630-C00091
    2H), 1.46 (s, 9H), 1.40 (d, J = 7.3 Hz, 3H), 0.97 (s, 3H), 0.95 (s, 3H).
    39 (2S)-2-{[(2S)-2-{[(4-bromo-2- 1H NMR (acetone-d6, 300 MHz) δ: 8.26
    fluorophenyl) carbamoyl]amino}-4- (t, J = 8.9 Hz, 1H), 8.08 (br. s., NH),
    methylpentanoyl]amino}propanoic 7.67 (d, J = 7.0 Hz, NH), 7.33 (dd, J =
    acid 10.8, 2.3 Hz, 1H), 7.27 (dt, J = 8.8, 1.8
    Figure US20220202777A1-20220630-C00092
    Hz, 1H), 6.52 (d, J = 9.1 Hz, NH), 4.40- 4.54 (m, 2H), 1.72-1.87 (m, 1H), 1.59-1.72 (m, 1H), 1.45-1.57 (m, 1H), 1.39 (d, J = 7.3 Hz, 3H), 0.95 (s, 3H), 0.93 (s, 3H).
    40 (2S)-N-[(1S)-2-amino-1-methyl-2- 1H NMR (acetone-d6, 300 MHz) δ: 8.25
    oxoethyl]-2-{[(4-bromo-2- (t, J = 8.8 Hz, 1H), 8.09 (br. s., NH),
    fluorophenyl) carbamoyl]amino}-4- 7.57 (d, J = 5.6 Hz, NH), 7.35 (dd, J =
    methylpentanamide 11.0, 2.2 Hz, 1H), 7.22-7.31 (m, 1H),
    Figure US20220202777A1-20220630-C00093
    6.92 (br. s., NH), 6.54 (d, J = 7.3 Hz, NH), 6.29 (br. s., NH), 4.30-4.44 (m, 2H), 1.73-1.90 (m, 1H), 1.47-1.72 (m, 2H), 1.30 (d, J = 7.0 Hz, 3H), 0.95 (d, J = 1.5 Hz, 3H), 0.93 (d, 3H).
    41 tert-butyl (2S)-2-{[(2S)-2-{[(4- 1H NMR (CDCl3, 300 MHz) δ: 7.62 (br.
    bromophenyl) carbamoyl}amino)- s., NH), 7.21-7.29 (m, 2H), 7.08-7.16
    4-methylpentanoyl] (m, 2H), 6.90 (br. s., NH), 4.39-4.50
    amino}propanoate (m, 1H), 4.35 (t, J = 7.0 Hz, 1H), 1.73-
    Figure US20220202777A1-20220630-C00094
    1.86 (m, 1H), 1.54-1.67 (m, 2H), 1.45 (s, 9H), 1.38 (d, 3H), 0.97 (d, J = 2.9 Hz, 3H), 0.95 (d, J = 2.9 Hz, 3H).
    42 tert-butyl (2S)-2-{[(2S)-2-{[(4- 1H NMR (CDCl3, 300 MHz) δ: 7.45 (br.
    bromophenyl) carbamoyl]amino}- s., NH), 7.21-7.30 (m, 2H), 7.10-7.18
    4-methylpentanoyl]amino}-3- (m, 2H), 4.45 (t, J = 7.2 Hz, 1H), 4.32
    methylbutanoate (dd, J = 8.5, 5.0 Hz, 1H), 2.07-2.20
    Figure US20220202777A1-20220630-C00095
    (m, 1H), 1.77 (dt, J = 13.3, 6.8 Hz, 1H), 1.56-1.67 (m, 2H), 1.47 (s, 9H), 0.98 (d, J = 2.3 Hz, 3H), 0.96 (d, 3H), 0.93 (s, 3H), 0.91 (s, 3H).
    43 (2S)-2-{[(2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ: 8.22
    carbamoyl]amino}-4- (s, NH), 7.66 (d, J = 6.4 Hz, NH), 7.43-
    methylpentanoyl]amino}propanoic 7.50 (m, 2H), 7.34-7.41 (m, 2H), 6.05
    acid (d, J = 7.9 Hz, NH), 4.39-4.52 (m,
    Figure US20220202777A1-20220630-C00096
    2H), 2.81 (br. s., 4H), 1.71-1.86 (m, 1H), 1.57-1.71 (m, 1H), 1.43-1.57 (m, 1H), 1.39 (d, J = 7.3 Hz, 3H), 0.94 (s, 3H), 0.92 (s, 3H).
    44 (2S)-2-{[(2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ: 7.45
    carbamoyl]amino}-4- (br. s., NH), 7.21-7.30 (m, 2H), 7.10-
    methylpentanoyl]amino}-3- 7.18 (m, 2H), 4.45 (t, J = 7.2 Hz, 1H),
    methylbutanoic acid 4.32 (dd, J = 8.5, 5.0 Hz, 1H), 2.07-
    Figure US20220202777A1-20220630-C00097
    2.20 (m, 1H), 1.77 (dt, J = 13.3, 6.8 Hz, 1H), 1.56-1.67 (m, 2H), 1.47 (s, 9H), 0.98 (d, J = 2.3 Hz, 3H), 0.96 (d, 3H), 0.93 (s, 3H), 0.91 (s, 3H).
    45 (2S)-N-[(1S)-2-amino-1-methyl-2- 1H NMR (acetone-d6, 300 MHz) δ: 8.21
    oxoethyl]-2-{[(4-bromophenyl) (s, NH), 7.56 (s, NH), 7.42-7.49 (m,
    carbamoyl]amino}-4- 2H), 7.33-7.40 (m, 2H), 6.06-6.12 (s,
    methylpentanamide NH), 4.28-4.44 (m, 2H), 1.70-1.89
    Figure US20220202777A1-20220630-C00098
    (m, 1H), 1.59-1.70 (m, 1H), 1.47- 1.59 (m, 1H), 1.30 (d, J = 7.3 Hz, 3H), 0.95 (s, 3H), 0.92 (s, 3H).
    46 (2S)-N-[(1S)-1-(amino-3-methyl-1- 1H NMR (CD3OD, 300 MHz) δ: 7.34-
    oxobutan-2-yl]-2-{[(4- 7.40 (m, 2H), 7.26-7.33 (m, 2H), 4.34
    bromophenyl) carbamoyl]amino}- (dd, J = 9.5, 5.4 Hz, 1H), 4.21 (d, J =
    4-methylpentanamide 7.0 Hz, 1H), 2.02-2.16 (m, 1H), 1.67-
    Figure US20220202777A1-20220630-C00099
    1.79 (m, 1H), 1.51-1.65 (m, 1H), 0.94- 1.00 (m, 9H).
    47 (2S)-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.93
    carbamoyl]amino}-N-(2-hydroxy- (s, NH), 7.33-7.40 (m, 2H), 7.26-
    2-methylpropyl)-4- 7.33 (m, 2H), 6.28 (br. s., NH), 4.25-
    methylpentanamide 4.36 (m, 1H), 3.15-3.27 (m, 2H), 1.67-
    Figure US20220202777A1-20220630-C00100
    1.81 (m, 1H), 1.50-1.67 (m, 2H), 1.17 (s, 6H), 0.99 (d, J = 4.7 Hz, 3H), 0.97 (d, 3H).
    48 (2S)-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    carbamoyl]amino}-N-[2-hydroxy- 7.41 (m, 2H), 7.26-7.33 (m, 2H), 4.30
    1-(hydroxymethyl)ethyl]-4- (dd, J = 9.4, 5.6 Hz, 1H), 3.86-3.96
    methylpentanamide (m, 1H), 3.62 (t, J = 5.6 Hz, 4H), 1.67-
    Figure US20220202777A1-20220630-C00101
    1.81 (m, 1H), 1.52-1.67 (m, 2H), 0.98 (d, J = 3.8 Hz, 3H), 0.96 (d, 3H).
    47 (2S)-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    carbamoyl]amino}-N-(2,3- 7.41 (m, 2H), 7.27-7.34 (m, 2H), 4.28
    dihydroxypropyl)-4- (dd, J = 8.9, 5.1 Hz, 1H), 3.64-3.76
    methylpentanamide (m, 1H), 3.46-3.52 (m, 2H), 3.33-
    Figure US20220202777A1-20220630-C00102
    3.42 (m, 1H), 3.15-3.27 (m, 1H), 1.67- 1.80 (m, 1H), 1.48-1.67 (m, 2H), 0.98 (d, J = 4.7 Hz, 3H), 0.96 (d, 3H).
    48 (2S)-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    carbamoyl]amino}-N-[(1R)-2- 7.40 (m, 2H), 7.26-7.32 (m, 2H), 4.26
    hydroxy-1-methylethyl]-4- (dd, J = 8.2, 6.7 Hz, 1H), 3.88-3.99
    methylpentanamide (m, 1H), 3.49 (dd, J = 5.4, 1.3 Hz, 2H),
    Figure US20220202777A1-20220630-C00103
    1.72 (dt, J = 13.3, 6.8 Hz, 1H), 1.50- 1.60 (m, 2H), 1.14 (d, J = 6.7 Hz, 3H), 0.98 (d, J = 3.8 Hz, 3H), 0.96 (d, 3H).
    49 tert-butyl (2S)-2-{[(2S)-2-{[4- 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    bromophenyl)carbamoyl]amino}-4- 7.39 (m, 2H), 7.27-7.32 (m, 2H), 4.36
    methyl pentanoyl] (dd, J = 9.5, 5.4 Hz, 1H), 4.26 (dd, J =
    amino}propanoate 8.6, 5.4 Hz, 1H), 1.49-1.84 (m, 6H),
    Figure US20220202777A1-20220630-C00104
    1.45 (s, 9H), 1.36-1.43 (m, 1H), 0.99 (d, J = 4.4 Hz, 3H), 0.97 (d, J = 4.1 Hz, 3H), 0.90-0.96 (m, 3H).
    50 tert-butyl (2S)-{[(2S)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.32-
    bromophenyl)carbamoyl]amino}-4- 7.43 (m, 6H), 7.25-7.31 (m, 2H), 4.41
    methylpentanoyl]amino}(phenyl) (dd, J = 9.4, 5.3 Hz, 1H), 1.72-1.81
    ethanoate (m, 1H), 1.49-1.70 (m, 2H), 1.40 (s,
    Figure US20220202777A1-20220630-C00105
    9H), 1.17-1.19 (m, 0H), 0.99 (t, J = 6.7 Hz, 6H).
    51 (2S)-2-{[(2S)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    bromophenyl)carbamoyl]amino}-4- 7.40 (m, 2H), 7.25-7.33 (m, 2H), 4.32-
    methylpentanoyl]amino}pentanoic 4.44 (m, 2H), 1.35-1.90 (m, 7H),
    acid 0.99 (d, J = 3.8 Hz, 3H), 0.97 (d, J = 3.8
    Figure US20220202777A1-20220630-C00106
    Hz, 3H), 0.91-0.96 (m, 3H).
    52 (2S)-{[(2S)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.40-
    bromophenyl)carbamoyl]amino}-4- 7.47 (m, 2H), 7.23-7.39 (m, 7H), 4.41
    methylpentanoyl]amino}(phenyl) (dd, J = 9.4, 5.3 Hz, 1H), 1.70-1.84
    ethanoic acid (m, 1H), 1.48-1.69 (m, 2H), 0.98 (t,
    Figure US20220202777A1-20220630-C00107
    6H).
    53 (2S)-N-[(2S)-1-amino-1-oxopentan- 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    2-yl]-2-{[(4- 7.41 (m, 2H), 7.26-7.33 (m, 2H), 4.30
    bromophenyl)carbamoyl]amino}-4- (ddd, J = 16.0, 9.4, 5.1 Hz, 1H), 1.50-
    methylpentanamide 1.86 (m, 5H), 1.33-1.48 (m, 2H), 0.95-
    Figure US20220202777A1-20220630-C00108
    1.01 (m, 6H), 0.89-0.96 (m, 3H).
    54 (2S)-N-[(1S)-2-amino-2-oxo-1- 1H NMR (CD3OD, 300 MHz) δ: 7.41-
    phenylethyl]-2-{[(4- 7.48 (m, 2H), 7.24-7.42 (m, 7H), 4.36
    bromophenyl)carbamoyl]amino}-4- (dd, J = 9.7, 5.0 Hz, 1H), 1.52-1.82
    methylpentanamide (m, 3H), 0.92-1.02 (m, 6H).
    Figure US20220202777A1-20220630-C00109
    55 tert-butyl {[2-{[(4-bromophenyl) 1H NMR (CDCl3, 300 MHz) δ: 7.30-
    carbamoyl]amino}-2,4- 7.39 (m, 2H), 7.15-7.23 (m, 2H), 6.82
    dimethylpentanoyl]amino}acetate (br. s., 1H), 2.15-2.32 (m, 1H), 1.68-
    Figure US20220202777A1-20220630-C00110
    1.79 (m, 2H), 1.63 (s, 3H), 1.48 (s, 9H), 0.93 (d, J = 6.4 Hz, 3H), 0.89 (d, J = 6.2 Hz, 3H).
    56 {[2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.31
    carbamoyl]amino}-2,4- (d, J = 14.4 Hz, 2H), 3.92 (d, J = 1.2
    dimethylpentanoyl] amino}acetic Hz, 2H), 2.03-2.15 (m, 1H), 1.70-
    acid 1.86 (m, 2H), 1.58 (s, 3H), 0.95 (d, J =
    Figure US20220202777A1-20220630-C00111
    6.4 Hz, 3H), 0.91 (d, J = 6.4 Hz, 3H).
    57 tert-butyl {[2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ:
    carbamoyl]amino}-2- 7.247.39 (m, 2H), 7.24 (m, 2H), 6.50 (s,
    ethylbutanoyl] amino}acetate NH), 3.85 (s, 2H), 2.21-2.40 (m, 2H),
    Figure US20220202777A1-20220630-C00112
    1.82 (dq, J = 14.2, 7.3 Hz, 2H), 1.45 (s, 9H), 0.85 (t, J = 7.3 Hz, 6H).
    58 {[2-{[(4-bromophenyl) 1H NMR (CD3OD, 600 MHz) δ: 7.35
    carbamoyl]amino}-2- (d, J = 8.8 Hz, 2H), 7.26-7.30 (m, 2H),
    ethylbutanoyl]amino}acetic acid 3.92 (s, 2H), 2.23-2.34 (m, 2H), 1.78-
    Figure US20220202777A1-20220630-C00113
    1.89 (m, 2H), 0.85 (t, J = 7.5 Hz, 6H).
    59 tert-butyl {[2-{[(4-bromophenyl) 1H NMR (CDCl3, 300 MHz) δ: 7.23
    carbamoyl]amino}-2- (m, 2H), 7.39 (m, 2H), 3.81 (s, 2H),
    methylpropanoyl]amino}acetate 1.52 (s, 6H), 1.45 (s, 9H).
    Figure US20220202777A1-20220630-C00114
    60 {[2-{[(4-bromophenyl) 1H NMR (CDCl3, 300 MHz) δ: 7.23-
    carbamoyl]amino}-2- 7.40 (m, 4H), 3.81 (s, 2H), 1.51 (s, 6H).
    methylpropanoyl] amino}acetic
    acid
    Figure US20220202777A1-20220630-C00115
    61 (2S)-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.34-
    carbamoyl]amino}-N-[2- 7.39 (m, 2H), 7.28-7.33 (m, 2H), 4.36
    (dimethylamino)-2-oxoethyl]-4- (dd, J = 10.0, 4.7 Hz, 1H), 3.97-4.13
    methylpentanamide (m, 2H), 3.03 (s, 3H), 2.94 (s, 3H), 1.51-
    Figure US20220202777A1-20220630-C00116
    1.83 (m, 3H), 0.94-1.03 (m, 6H).
    62 tert-butyl {[(2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.49-
    (trifluoromethyl)phenyl]carbamoyl} 7.56 (m, 4H), 4.36 (dd, J = 9.7, 5.3 Hz,
    amino)pentanoyl]amino}acetate 1H), 3.70-3.95 (m, 2H), 1.69-1.86
    Figure US20220202777A1-20220630-C00117
    (m, 1H), 1.51-1.68 (m, 2H), 1.43- 1.46 (m, 9H), 0.99 (dd, J = 6.4, 4.1 Hz, 6H).
    63 {[(2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.50-
    (trifluoromethyl)phenyl]carbamoyl} 7.56 (m, 4H), 6.37 (d, J = 7.6 Hz, NH),
    amino)pentanoyl]amino}acetic 4.38 (dd, J = 9.7, 5.0 Hz, 1H), 3.79-
    acid 4.04 (m, 2H), 1.69-1.87 (m, 1H), 1.50-
    Figure US20220202777A1-20220630-C00118
    1.70 (m, 2H), 0.99 (dd, J = 6.4, 3.8 Hz, 6H).
    64 tert-butyl {[(2R,3R)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    bromophenyl)carbamoyl]amino}-3- 7.39 (m, 2H), 7.26-7.32 (m, 2H), 6.29
    methylpentanoyl]amino}acetate (s, NH), 4.17-4.24 (m, 0H), 3.73-
    Figure US20220202777A1-20220630-C00119
    3.95 (m, 2H), 1.87 (dtd, J = 9.8, 6.5, 3.2 Hz, 0H) 1.61 (ddt, J = 17.0, 7.4, 3.6 Hz, 0H), 1.43-1.47 (m, 9H), 1.11- 1.27 (m, 0H), 0.90-1.03 (m, 6H).
    65 {[(2R,3R)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    bromophenyl)carbamoyl]amino}-3- 7.39 (m, 2H), 7.27-7.32 (m, 2H), 6.29
    methylpentanoyl]amino}acetic (s, NH), 4.19-4.26 (m, 1H), 3.81-
    acid 4.00 (m, 2H), 1.84-1.94 (m, 1H), 1.60
    Figure US20220202777A1-20220630-C00120
    (ddd, J = 13.2, 7.6, 3.5 Hz, 1H), 1.13- 1.30 (m, 2H), 1.13-1.30 (m, 2H), 0.96 (d, J = 17.6 Hz, 3H).
    66 tert-butyl {[(2R)-2-{[(4- 1H NMR (CD3OD, 600 MHz) δ: 7.35-
    bromophenyl)carbamoyl]amino}-4- 7.38 (m, 2H), 7.28-7.31 (m, 2H), 4.34
    methylpentanoyl]amino}acetate (dd, J = 10.0, 5.0 Hz, 1H), 3.75-3.91
    Figure US20220202777A1-20220630-C00121
    (m, 2H), 1.73-1.80 (m, 1H), 1.63- 1.68 (m, 1H), 1.53-1.59 (m, 1H), 1.44- 1.47 (m, 9H), 0.99 (d, J = 6.7 Hz, 3H), 0.97 (d, J = 6.7 Hz, 3H).
    67 {[(2R)-2-{[(4- 1H NMR (CD3OD, 600 MHz) δ: 7.34-
    bromophenyl)carbamoyl]amino}-4- 7.39 (m, 2H), 7.26-7.32 (m, 2H), 4.32-
    methylpentanoyl]amino}acetic 4.38 (m, 1H), 3.84-4.00 (m, 2H),
    acid 1.72-1.81 (m, 1H), 1.63-1.70 (m,
    Figure US20220202777A1-20220630-C00122
    1H), 1.52-1.60 (m, 1H), 0.99 (d, J = 6.7 Hz, 3H), 0.97 (d, J = 6.7 Hz, 3H).
    68 tert-butyl {[(2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.27-
    (methylsulfanyl)phenyl]carbamoyl} 7.34 (m, 2H), 7.17-7.24 (m, 2H), 6.24
    amino)pentanoyl]amino}acetate (d, J = 7.9 Hz, NH), 4.30-4.40 (m,
    Figure US20220202777A1-20220630-C00123
    1H), 3.72-3.95 (m, 2H), 2.40-2.43 (m, 3H), 1.69-1.84 (m, 1H), 1.50- 1.68 (m, 2H), 1.44-1.47 (m, 9H), 0.99 (dd, J = 6.4, 4.7 Hz, 6H).
    69 2-methyl-2-{[(2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 8.27
    (trifluoromethyl)phenyl]carbamoyl} (s, NH), 7.52 (d, J = 19.9 Hz, 4H), 6.29
    amino)pentanoyl]amino} (d, J = 8.5 Hz, NH), 4.27-4.43 (m,
    propanoic acid 1H), 1.70-1.85 (m, 1H), 1.45-1.67
    Figure US20220202777A1-20220630-C00124
    (m, 8H), 0.98 (dd, J = 6.4, 2.9 Hz, 6H).
    70 {[(2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.26-
    (methylsulfanyl)phenyl]carbamoyl} 7.34 (m, 2H), 7.17-7.24 (m, 2H), 4.30-
    amino)pentanoyl]amino}acetic 4.41 (m, 1H), 3.80-4.03 (m, 2H),
    acid 2.39-2.43 (m, 3H), 1.49-1.84 (m,
    Figure US20220202777A1-20220630-C00125
    3H), 0.98 (dd, J = 6.4, 4.1 Hz, 6H).
    71 tert-butyl ({(2S)-4-methyl-2-[({4- 1H NMR (CD3OD, 300 MHz) δ: 7.52-
    [(trifluoromethyl)sulfanyl]phenyl} 7.57 (m, 2H), 7.47-7.52 (m, 2H), 4.32-
    carbamoyl)amino]pentanoyl}amino) 4.40 (m, 1H), 3.72-3.95 (m, 2H),
    acetate 1.69-1.84 (m, 1H), 1.50-1.68 (m,
    Figure US20220202777A1-20220630-C00126
    2H), 1.42-1.47 (m, 9H), 0.99 (dd, J = 6.3, 4.2 Hz, 6H).
    72 ({(2S)-4-methyl-2-[({4- 1H NMR (CD3OD, 300 MHz) δ: 7.47-
    [(trifluoromethyl)sulfanyl]phenyl} 7.57 (m, 4H), 4.37 (dd, J = 9.5, 5.1 Hz,
    carbamoyl)amino]pentanoyl}amino) 1H), 3.83-4.02 (m, 2H), 1.70-1.83
    acetic acid (m, 1H), 1.51-1.68 (m, 2H), 0.99 (d,
    Figure US20220202777A1-20220630-C00127
    J = 3.8 Hz, 3H), 0.97 (d, J = 3.8 Hz, 3H).
    73 tert-butyl 2-{[(2S)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    bromophenyl)carbamoyl]amino}-4- 7.38 (m, 2H), 7.26-7.32 (m, 2H), 4.31
    methylpentanoyl]amino}-2- (dd, J = 9.1, 5.6 Hz, 1H), 1.67-1.80
    methylpropanoate (m, 1H), 1.45-1.63 (m, 2H), 1.39-
    Figure US20220202777A1-20220630-C00128
    1.44 (m, 15H), 0.97 (dd, J = 6.6, 3.1 Hz, 6H).
    74 2-{[(2S)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 8.46
    bromophenyl)carbamoyl]amino}-4- (s, NH), 8.26 (s, NH), 7.33-7.38 (m,
    methylpentanoyl]amino}-2- 2H), 7.25-7.31 (m, 2H), 4.32 (dd, J =
    methylpropanoic acid 9.2, 5.4 Hz, 1H), 1.68-1.80 (m, 1H),
    Figure US20220202777A1-20220630-C00129
    1.51-1.65 (m, 2H), 1.49 (s, 3H), 1.48 (s, 3H), 0.98 (d, J = 3.5 Hz, 3H), 0.96 (d, J = 3.5 Hz, 3H).
    75 tert-butyl {[(2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.61
    (methylsulfinyl)phenyl]carbamoyl} (s, 4H), 4.37 (dd, J = 9.8, 5.1 Hz, 1H),
    amino)pentanoyl]amino}acetate 3.72-3.96 (m, 2H), 2.77 (s, 3H), 1.69-
    Figure US20220202777A1-20220630-C00130
    1.85 (m, 1H), 1.51-1.69 (m, 2H), 1.45 (s, 9H), 0.94-1.05 (m, 6H).
    76 tert-butyl {[(2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.77-
    (methylsulfonyl)phenyl]carbamoyl} 7.86 (m, 2H), 7.57-7.67 (m, 2H), 4.37
    amino)pentanoyl]amino}acetate (dd, J = 9.7, 5.0 Hz, 1H), 3.71-3.96
    Figure US20220202777A1-20220630-C00131
    (m, 2H), 3.07 (s, 3H), 1.69-1.83 (m, 1H), 1.51-1.70 (m, 2H), 1.40-1.49 (m, 9H), 0.94-1.03 (m, 6H).
    77 {[(2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.57-
    (methylsulfinyl)phenyl]carbamoyl} 7.66 (m, 4H), 4.38 (dd, J = 9.7, 5.0 Hz,
    amino)pentanoyl]amino}acetic 1H), 3.81-4.03 (m, 2H), 2.77 (s, 3H),
    acid 1.69-1.85 (m, 1H), 1.48-1.68 (m,
    Figure US20220202777A1-20220630-C00132
    2H), 0.92-1.03 (m, 6H).
    78 {[(2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.76-
    (methylsulfonyl)phenyl]carbamoyl} 7.87 (m, 2H), 7.57-7.68 (m, 2H), 6.43
    amino)pentanoyl]amino}acetic (d, J = 8.5 Hz, NH), 4.32-4.45 (m,
    acid 1H), 3.81-4.04 (m, 2H), 3.07 (s, 3H),
    Figure US20220202777A1-20220630-C00133
    1.71-1.83 (m, 1H), 1.49-1.70 (m, 2H), 0.98 (dd, J = 6.4, 3.5 Hz, 6H).
    79 tert-butyl 2-methyl-2-{[(2S)-4- 1H NMR (CD3OD, 300 MHz) δ: 7.46-
    methyl-2-({[4- 7.58 (m, 2H), 4.33 (dd, J = 9.2, 5.7 Hz,
    (trifluoromethyl)phenyl]carbamoyl} 1H), 1.69-1.86 (m, 1H), 1.46-1.66
    amino)pentanoyl]amino} (m, 2H), 1.36-1.46 (m, 15H), 0.94-
    propanoate 1.04 (m, 6H).
    Figure US20220202777A1-20220630-C00134
    80 tert-butyl {[(2S)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.24-
    bromophenyl)carbamoyl]amino}-4- 7.41 (m, 4H), 4.44 (dd, J = 7.8, 5.4 Hz,
    (methylsulfanyl)butanoyl]amino} 1H), 3.70-3.99 (m, 2H), 2.54-2.68
    acetate (m, 2H), 2.12-2.18 (m, 1H), 2.11 (s,
    Figure US20220202777A1-20220630-C00135
    3H), 1.85-2.02 (m, 1H), 1.41-1.50 (m, 9H). [α]D = −21.8 (c = 1.00, MeOH)
    81 tert-butyl {[(2S)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.26-
    bromophenyl)carbamoyl]amino}-4- 7.43 (m, 4H), 4.43-4.57 (m, 1H), 3.70-
    (methylsulfonyl)butanoyl]amino} 4.03 (m, 2H), 3.24 (s, 2H), 2.99 (s,
    acetate 4H), 2.28-2.42 (m, 1H), 2.11-2.26
    Figure US20220202777A1-20220630-C00136
    (m, 1H), 1.47 (s, 9H).
    82 {[(2S)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.25-
    bromophenyl)carbamoyl]amino}-4- 7.44 (m, 4H), 6.55 (d, J = 7.3 Hz, NH),
    (methylsulfanyl)butanoyl]amino} 4.53 (m, 1H), 3.79-4.10 (m, 2H), 3.26
    acetic acid (m., 2H), 2.98 (s, 3H), 2.26-2.42 (m,
    Figure US20220202777A1-20220630-C00137
    1H), 2.20 (m, 1H).
    83 {[(2S)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.26-
    bromophenyl)carbamoyl]amino}-4- 7.42 (m, 4H), 6.55 (d, J = 7.3 Hz, NH),
    (methylsulfonyl)butanoyl]amino} 4.47-4.58 (m, 1H), 3.80-4.11 (m,
    acetic acid 2H), 3.25 (m, 2H), 2.98 (s, 3H), 2.28-
    Figure US20220202777A1-20220630-C00138
    2.43 (m, 1H), 2.11-2.27 (m, 1H).
    84 tert-butyl {[2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.61
    bromophenyl)carbamoyl]amino}-3- (s, 1H), 7.21-7.41 (m, 4H), 6.94 (s,
    (1H-imidazol-4- 1H), 4.51-4.64 (m, 1H), 3.75-3.96
    yl)propanoyl]amino}acetate (m, 2H), 3.07-3.22 (m, 1H), 2.93-
    Figure US20220202777A1-20220630-C00139
    3.06 (m, 1H), 1.49 (s, 9H).
    85 {[2-{[(4- 1H NMR (DMSO-D6, 300 MHz) δ: 8.93
    bromophenyl)carbamoyl]amino}-3- (NH, 1H), 8.42 (br. s., NH), 7.67 (s,
    (1H-imidazol-4- 1H), 7.34 (d, J = 4.1 Hz, 4H), 6.88 (s,
    yl)propanoyl]amino}acetic 1H), 6.28 (d, J = 7.3 Hz, NH), 4.44 (m.,
    acid 1H), 3.55-3.90 (m, 2H), 2.93 (m., 2H).
    Figure US20220202777A1-20220630-C00140
    86 tert-butyl 2-{[(2R)-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    bromophenyl)carbamoyl]amino}-4- 7.38 (m, 2H), 7.26-7.32 (m, 2H), 4.31
    methylpentanoyl]amino}-2- (dd, J = 9.1, 5.6 Hz, 1H), 1.67-1.80
    methylpropanoate (m, 1H), 1.45-1.63 (m, 2H), 1.39-
    Figure US20220202777A1-20220630-C00141
    1.44 (m, 15H), 0.97 (dd, J = 6.6, 3.1 Hz, 6H).
    87 2-{[(2R)-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 8.46
    carbamoyl]amino}-4- (s, NH), 8.23 (s, 2NH), 7.33-7.39 (m,
    methylpentanoyl] amino}-2- 2H), 7.26-7.31 (m, 2H), 6.19 (d, J =
    methylpropanoic acid 8.2 Hz, NH), 4.31 (m 1H), 1.73 (m,
    Figure US20220202777A1-20220630-C00142
    1H), 1.51-1.65 (m, 2H), 1.49 (s, 3H), 1.48 (s, 3H), 0.98 (d, J = 3.8 Hz, 6H), 0.96 (d, J = 3.5 Hz, 6H).
    88 tert-butyl {[4-amino-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.27-
    bromophenyl) carbamoyl]amino}- 7.42 (m, 4H), 4.69 (t, J = 6.0 Hz, 1H),
    4-oxobutanoyl]amino}acetate 3.75-3.94 (m, 2H), 2.70-2.78 (m,
    Figure US20220202777A1-20220630-C00143
    2H), 1.45 (s, 9H).
    89 4-amino-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.26-
    carbamoyl]amino}-4-oxobutanoic 7.44 (m, 4H), 4.62 (t, J = 5.3 Hz, 1H),
    acid 2.70-2.94 (m, 2H).
    Figure US20220202777A1-20220630-C00144
    90 tert-butyl {[2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.56-
    carbamoyl]amino}-3-(1H-indol-3- 7.61 (m, 1H), 7.30-7.36 (m, 3H), 7.23-
    yl) propanoyl]amino}acetate 7.26 (m, 2H), 7.16 (s, NH), 7.08 (td,
    Figure US20220202777A1-20220630-C00145
    J = 7.6, 1.2 Hz, 1H), 6.95-7.02 (m, 1H), 6.13 (d, J = 7.3 Hz, NH), 4.60-4.68 (m, 1H), 3.80 (s, 2H), 3.32-3.38 (m, 1H), 3.11-3.23 (m, 1H), 1.43-1.47 (m, 9H).
    91 tert-butyl {[4-amino-2-{[(4- 1H NMR (CD3OD, 300 MHz) δ: 7.27-
    bromophenyl) carbamoyl]amino}- 7.42 (m, 4H), 4.69 (t, J = 6.0 Hz, 1H),
    4-oxobutanoyl]amino}acetate 3.75-3.94 (m, 2H), 2.70-2.78 (m,
    Figure US20220202777A1-20220630-C00146
    2H), 1.45 (s, 9H).
    Interm. IUPAC name
    No. Structure 1H NMR δ (ppm)
    10 (2S,3S)-2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.33-
    carbamoyl]amino}-3- 7.41 (m, 2H), 7.26-7.33 (m, 2H), 4.18
    methylpentanamide (d, J = 6.2 Hz, 1H), 1.74-1.91 (m, 1H),
    Figure US20220202777A1-20220630-C00147
    1.50-1.66 (m, 1H), 1.11-1.33 (m, 1H), 0.99 (d, J = 7.0 Hz, 3H), 0.91- 0.97 (m, 3H).
    11 (2S,3S)-2-{[(4-bromo-2- 1H NMR (CD3OD, 300 MHz) δ: 7.99
    fluorophenyl) carbamoyl]amino}-3- (t, J = 8.8 Hz, 1H), 7.31 (dd, J = 10.7,
    methylpentanamide 2.2 Hz, 1H), 7.19-7.27 (m, 1H), 4.18
    Figure US20220202777A1-20220630-C00148
    (d, J = 6.2 Hz, 1H), 1.78-1.95 (m, 1H), 1.49-1.65 (m, 1H), 1.10-1.27 (m, 1H), 1.00 (d, J = 6.7 Hz, 3H), 0.91- 0.98 (m, 3H).
    12 (2S)-2-{[(4-bromo-2-fluorophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}-pentanamide 8.28 (t, J = 8.8 Hz, 1H), 8.12 (br. s.,
    Figure US20220202777A1-20220630-C00149
    NH), 7.33 (dd, J = 11.0, 2.2 Hz, 1H), 7.26 (dt, J = 8.9, 1.9 Hz, 1H), 7.07 (br. s., NH), 6.55 (d, J = 7.0 Hz, NH), 6.40 (br. s., NH), 4.38 (td, J = 7.8, 5.3 Hz, 1H), 1.73-1.89 (m, 1H), 1.54-1.70 (m, 1H), 1.24-1.49 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H).
    13 (2S)-2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}-4- 8.17 (s, NH), 7.41-7.50 (m, 2H), 7.33-
    methylpentanamide 7.40 (m, 2H), 6.03 (d, J = 8.2 Hz,
    Figure US20220202777A1-20220630-C00150
    NH), 4.39 (ddd, J = 9.4, 8.2, 5.0 Hz, 1H), 3.58 (q, J = 5.6 Hz, 2H), 3.26- 3.37 (m, 2H), 1.66-1.81 (m, 1H), 1.44- 1.67 (m, 2H), 0.94 (d, J = 1.5 Hz, 3H), 0.92 (d, J = 1.4 Hz, 3H).
    14 (2S)-2({[(4-bromo-2-fluorophenyl) 1H NMR (acetone-d6, 300 MHz) δ: 8.27
    carbamoyl]amino}-4- (t, J = 8.9 Hz, 1H), 8.06 (br. s., NH),
    methylpentanoate 7.34 (dd, J = 10.8, 2.3 Hz, 1H), 7.25-
    Figure US20220202777A1-20220630-C00151
    7.31 (m, 1H), 6.53 (d, J = 7.0 Hz, NH), 4.43-4.55 (m, 1H), 1.73-1.87 (m, 1H), 1.53-1.71 (m, 2H), 0.98 (d, J = 1.5 Hz, 3H), 0.96 (d, J = 1.5 Hz, 3H).
    15 (2S)-2-{[(4-bromo-2-fluorophenyl) 1H NMR (acetone-d6, 300 MHz) δ: 8.28
    carbamoyl]amino}-4- (t, J = 8.9 Hz, 1H), 8.07 (br. s., NH),
    methylpentanamide 7.33 (dd, J = 10.8, 2.3 Hz, 1H), 7.23-
    Figure US20220202777A1-20220630-C00152
    7.30 (m, 1H), 7.10 (br. s., NH), 6.50 (d, J = 8.2 Hz, NH), 6.38 (br. s., NH), 4.42 (ddd, J = 9.6, 8.3, 5.0 Hz, 1H), 1.70- 1.87 (m, 1H), 1.59-1.70 (m, 1H), 1.44- 1.59 (m, 1H), 0.95 (d, J = 1.5 Hz, 3H), 0.93 (d, 3H).
    16 tert-butyl (2S)-2-{[(4-bromo-2- 1H NMR (CDCl3, 300 MHz) δ: 7.89 (t,
    fluorophenyl) carbamoyl]amino}-4- J = 8.8 Hz, 1H), 7.14 (dd, J = 10.4, 2.2
    methylpentanoate Hz, 1H), 7.06 (d, J = 9.1 Hz, 1H), 6.80
    Figure US20220202777A1-20220630-C00153
    (d, J = 2.6 Hz, NH), 5.79 (br. s., NH), 4.45 (dd, J = 8.8, 5.0 Hz, 1H), 1.69- 1.85 (m, 1H), 1.57-1.69 (m, 1H), 1.52 (s, 9H), 1.41-1.48 (m, 1H), 0.97 (d, J = 3.5 Hz, 3H), 0.95 (d, 3H).
    17 2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.31-
    carbamoyl]amino}-2,4- 7.39 (m, 2H), 7.22-7.30 (m, 2H), 1.80-
    dimethylpentanoic acid 1.92 (m, 2H), 1.71-1.82 (m, 1H),
    Figure US20220202777A1-20220630-C00154
    1.56-1.67 (m, 2H), 1.44 (s, 3H), 0.98 (d, J = 1.2 Hz, 3H), 0.95 (d, J = 1.2 Hz, 3H).
    18 tert-butyl {[2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 9.29
    carbamoyl]amino}-2- (br. s., NH), 8.58-8.75 (m, 4H), 7.33
    methylpropanoate (br. s., NH), 2.65-2.75 (m, 9H).
    Figure US20220202777A1-20220630-C00155
    19 2-{[(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.32-
    carbamoyl]amino}-2- 7.37 (m, 2H), 7.24-7.29 (m, 2H), 1.52
    methylpropanoic acid (s, 6H).
    Figure US20220202777A1-20220630-C00156
    20 2-{[(4-bromophenyl) 1H NMR (acetone-d6, 300 MHz) δ:
    carbamoyl]amino}-2-ethylbutanoic 8.76 (br. s., 1H), 7.44-7.52 (m, 2H),
    acid 7.31-7.40 (m, 2H), 6.30 (br. s., 1H),
    Figure US20220202777A1-20220630-C00157
    2.29-2.48 (m, 2H), 1.75-1.92 (m, 2H), 0.76-0.86 (m, 6H).
    21 tert-butyl (2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.50
    (trifluoromethyl)phenyl]carbamoyl} (s, 4H), 4.27 (dd, J = 9.1, 5.6 Hz, 1H),
    amino)pentanoate 1.68-1.86 (m, 1H), 1.52-1.66 (m,
    Figure US20220202777A1-20220630-C00158
    2H), 1.45-1.50 (s, 9H), 0.95 (t, J = 6.9 Hz, 6H).
    22 (2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.49-
    (trifluoromethyl)phenyl]carbamoyl} 7.57 (m, 4H), 4.38 (dd, J = 9.4, 5.0 Hz,
    amino)pentanoic acid 1H), 1.69-1.87 (m, 1H), 1.51-1.69
    Figure US20220202777A1-20220630-C00159
    (m, 2H), 0.92-1.01 (m, 6H).
    23 tert-butyl (2S)-2-({(4-chlorophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.30-
    carbamoyl}amino)4- 7.39 (m, 2H), 7.17-7.28 (m, 1H), 4.25
    methylpentanoate (dd, J = 8.9, 5.7 Hz, 1H), 1.74 (dd, J =
    Figure US20220202777A1-20220630-C00160
    13.6, 7.5 Hz, 1H), 1.51-1.67 (m, 2H), 1.47 (s, 9H), 0.97 (t, J = 6.9 Hz, 6H).
    24 (2S)-2-({(4-chlorophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.29-
    carbamoyl}amino)4- 7.38 (m, 2H), 7.17-7.27 (m, 2H), 4.36
    methylpentanoic acid (dd, J = 9.4, 5.0 Hz, 1H), 1.73 (dd, J =
    Figure US20220202777A1-20220630-C00161
    18.3, 5.7 Hz, 1H), 1.51-1.68 (m, 2H), 0.98 (dd, J = 6.4, 3.5 Hz, 6H).
    25 tert-butyl (2S)-2-({(4-iodophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.50-
    carbamoyl}amino)4- 7.59 (m, 2H), 7.12-7.23 (m, 2H), 4.25
    methylpentanoate (m, 1H), 1.73 (m, 1H), 1.49-1.63 (m,
    Figure US20220202777A1-20220630-C00162
    2H), 1.47 (s, 9H), 0.91-1.03 (m, 6H).
    26 (2S)-2-({(4-iodophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.50-
    carbamoyl}amino)4- 7.58 (m, 2H), 7.13-7.21 (m, 2H), 4.35
    methylpentanoic acid (dd, J = 9.4, 5.0 Hz, 1H), 1.50-1.86
    Figure US20220202777A1-20220630-C00163
    (m, 2H), 1.01 (m, 6H).
    27 (2R,3R)-2-({(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.35-
    carbamoyl}amino)3- 7.39 (m, 2H), 7.28-7.32 (m, 2H), 4.32
    methylpentanoic acid (d, J = 4.7 Hz, 1H), 1.92 (dq, J = 6.8,
    Figure US20220202777A1-20220630-C00164
    4.6 Hz, 1H), 1.46-1.60 (m, 1H), 1.16- 1.33 (m, 1H), 0.93-1.02 (m, 6H).
    28 tert-butyl (2R)-2-({(4- 1H NMR (CDCl3, 300 MHz) δ: 7.33 (d,
    bromophenyl) carbamoyl}amino)4- J = 8.5 Hz, 2H), 7.17 (s, 2H), 4.43 (dd,
    methylpentanoate J = 9.1, 5.3 Hz, 1H), 1.68-1.79 (m,
    Figure US20220202777A1-20220630-C00165
    1H), 1.56-1.67 (m, 1H), 1.48 (s, 9H), 1.44 (s, 1H), 0.97 (d, J = 4.1 Hz, 3H), 0.95 (d, J = 4.4 Hz, 3H).
    29 (2R)-2-({(4-bromophenyl) 1H NMR (acetone-D6, 300 MHz) δ:
    carbamoyl}amino)4- 8.17 (s, NH), 7.43-7.50 (m, 2H), 7.33-
    methylpentanoic acid 7.41 (m, 2H), 6.04 (d, J = 7.9 Hz,
    Figure US20220202777A1-20220630-C00166
    NH), 4.42-4.52 (m, 1H), 1.71-1.87 (m, 1H), 1.52-1.69 (m, 2H), 0.97 (d, J = 2.1 Hz, 3H), 0.95 (d, J = 2.3 Hz, 3H).
    30 tert-butyl (2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.27-
    (methylthio)phenyl] 7.32 (m, 2H), 7.18-7.23 (m, 2H), 4.22-
    carbamoyl}amino)pentanoate 4.29 (m, 1H), 2.42 (s, 3H), 1.70-1.79
    Figure US20220202777A1-20220630-C00167
    (m, 1H), 1.51-1.61 (m, 2H), 1.47 (s, 9H), 0.97 (t, J = 6.7 Hz, 6H).
    31 (2S)-4-methyl-2-({[4- 1H NMR (CD3OD, 300 MHz) δ: 7.25-
    (methylthio)phenyl] 7.31 (m, 2H), 7.14-7.20 (m, 2H), 4.37
    carbamoyl}amino)pentanoic acid (dd, J = 9.2, 5.1 Hz, 1H), 2.39 (s, 3H),
    Figure US20220202777A1-20220630-C00168
    1.68- 1.83 (m, 1H), 1.51-1.67 (m, 2H), 0.96 (dd, J = 6.2, 2.3 Hz, 6H).
    32 (2S)-4-methyl-2-{({4- 1H NMR (CD3OD, 300 MHz) δ: 7.52-
    [(trifluoromethyl)thio]phenyl} 7.58 (m, 2H), 7.47-7.52 (m, 2H), 4.37
    carbamoyl}amino)pentanoic acid (dd, J = 9.4, 5.0 Hz, 1H), 1.70-1.82
    Figure US20220202777A1-20220630-C00169
    (m, 1H), 1.53-1.69 (m, 2H), 0.99 (d, J = 3.2 Hz, 3H), 0.97 (d, J = 3.2 Hz, 3H).
    33 tert-butyl (2S)-4-methyl-2-{({4- 1H NMR (CD3OD, 300 MHz) δ: 7.53-
    [(trifluoromethyl)thio]phenyl} 7.57 (m, 2H), 7.47-7.51 (m, 2H), 4.26
    carbamoyl}amino)pentanoate (dd, J = 8.9, 5.7 Hz, 1H), 1.74 (td, J =
    Figure US20220202777A1-20220630-C00170
    13.6, 6.7 Hz, 1H), 1.51-1.65 (m, 2H), 1.47 (s, 9H), 0.97 (t, J = 6.7 Hz, 6H).
    34 (2S)-2-({(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 7.23-
    carbamoyl}amino)4- 7.41 (m, 4H), 4.31-4.42 (m, 1H), 2.56
    (methylthio)butanoic acid (d, J = 15.5 Hz, 2H), 2.12-2.23 (m,
    Figure US20220202777A1-20220630-C00171
    1H), 2.08 (s, 3H), 1.98 (dt, J = 14.0, 7.2 Hz, 1H).
    35 2-({(4-bromophenyl) 1H NMR (CD3OD, 300 MHz) δ: 8.76
    carbamoyl}amino)3-(1H-imidazol- (s, 1H), 7.23-7.40 (m, 6H), 4.65 (m,
    4-yl)propanoic acid 1H), 3.03-3.27 (m, 2H).
    Figure US20220202777A1-20220630-C00172
  • Biological Data
  • Biological activity of compounds according to Formula II is set forth in Table 5 below. CHO-Gα16 cells stably expressing FPRL1 were cultured in (F12, 10% FBS, 1% PSA, 400 μg/ml geneticin and 50 μg/ml hygromycin) and HEK-Gqi5 cells stable expressing FPR1 were cultured in (DMEM high glucose, (0% FBS, 1% PSA, 400 μg/ml geneticin and 50 μg/ml hygromycin). In general, the day before the experiment, 18,000 cells/well were plated in a 384-well clear bottom poly-d-lysine coated plate. The following day the screening compound-induced calcium activity was assayed on the FLIPRTetra. The drug plates were prepared in 384-well microplates using the EP3 and the MultiPROBE robotic liquid handling systems. Compounds were tested at concentrations ranging from 0.61 to 10,000 nM. Results are expressed as EC50 (nM) and efficacy values.
  • TABLE 5
    FPRL-1
    Ga16-CHO
    EC50 (nM)
    IUPAC Name Compound (Rel. eff.)
    {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H-imidazol-4- 10.0 (0.95)
    yl)propanoyl]amino}acetic acid
    tert-butyl {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H- 263 (0.95)
    imidazol-4-yl)propanoyl]amino}acetate
    {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 247 (1.01)
    (methylsulfonyl)butanoyl]amino}acetic acid
    tert-butyl{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 1238 (0.97)
    (methylsulfonyl)butanoyl]amino}acetate
    {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 7 (1.03)
    (methylsulfanyl)butanoyl]amino}acetic acid
    tert-butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 127 (0.98)
    (methylsulfanyl)butanoyl]amino}acetate
    2-methyl-2-{[(2S)-4-methyl-2-({[4- 2.3 (0.92)
    (trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}propanoic acid
    tert-butyl2-methyl-2-{[(2S)-4-methyl-2-({[4- 1016 (1.07)
    (trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}propanoate
    {[(2S)-4-methyl-2-({[4- 459 (1.12)
    (methylsulfonyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid
    tert-butyl{[(2S)-4-methyl-2-({[4- 1083 (0.90)
    (methylsulfonyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate
    {[(2S)-4-methyl-2-({[4- 358 (1.21)
    (methylsulfinyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid
    tert-butyl {[(2S)-4-methyl-2-({[4- 668 (0.97)
    (methylsulfinyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate
    2-{[(2S)-2-({[(4-bromophenyl)amino]carbamoyl}amino)-4- 1 (0.96)
    methylpentanoyl] amino}-2-methylpropanoic acid
    tert-butyl 2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}- 133 (1.16)
    4-methylpentanoyl]amino}-2-methylpropanoate
    ({(2S)-4-methyl-2-[({4- 560 (1.07)
    [(trifluoromethyl)sulfanyl]phenyl}carbamoyl)amino]pentanoyl}amino)acetic
    acid
    tert-butyl ({(2S)-4-methyl-2-[({4- 3103 (0.78)
    [(trifluoromethyl)sulfanyl]phenyl}carbamoyl)amino]pentanoyl}amino)acetate
    {[(2S)-4-methyl-2-({[4- 2.95 (1.05)
    (methylsulfanyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid
    tert-butyl {[(2S)-4-methyl-2-({[4- 116 (0.98)
    (methylsulfanyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate
    {[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 1229 (0.97)
    methylpentanoyl]amino}acetic acid
    tert-butyl {[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 3657 (0.92)
    methylpentanoyl]amino}acetate
    {[(2R,3R)-2-{[(4-bromophenyl)carbamoyl]amino}-3- 19315 (0.45)
    methylpentanoyl]amino}acetic acid
    tert-butyl {[(2R,3R)-2-{[(4-bromophenyl)carbamoyl]amino}- 3974 (0.44)
    3-methylpentanoyl]amino}acetate
    {[(2S)-4-methyl-2-({[4- 1.8 (0.99)
    (trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetic acid
    tert-butyl {[(2S)-4-methyl-2-({[4- 309 (0.81)
    (trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}acetate
    {[(2R)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4- 1489 (0.87)
    methylpentanoyl]amino}acetic acid
    (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-[2- 1.4 (0.90)
    (dimethylamino)-2-oxoethyl]-4-methylpentanamide
    [(2-{[(4-bromophenyl)carbamoyl]amino}-2- 480 (0.99)
    methylpropanoyl)amino]acetic acid
    tert-butyl [(2-{[(4-bromophenyl)carbamoyl]amino}-2- 114 (1.02)
    methylpropanoyl)amino]acetate
    [(2-{[(4-bromophenyl)carbamoyl]amino}-2- 19 (1.04)
    ethylbutanoyl)amino]acetic acid
    tert-butyl [(2-{[(4-bromophenyl)carbamoyl]amino}-2- 31 (1.03)
    ethylbutanoyl)amino]acetate
    [(2-{[(4-bromophenyl)carbamoyl]amino}-2,4- 22 (0.98)
    dimethylpentanoyl)amino]acetic acid
    tert-butyl [(2-{[(4-bromophenyl)carbamoyl]amino}-2,4- 58 (0.98)
    dimethylpentanoyl)amino]acetate
    (2S)-N-[(1S)-2-amino-2-oxo-1-phenylethyl]-2-{[(4- 84 (0.99)
    bromophenyl)carbamoyl]amino}-4-methylpentanamide
    (2S)-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 9.1 (1.08)
    methylpentanoyl]amino}(phenyl)ethanoic acid
    tert-butyl (2S)-{[(2S)-2-{[(4- 122 (1.02)
    bromophenyl)carbamoyl]amino}-4-
    methylpentanoyl]amino}(phenyl)ethanoate
    (2S)-N-[(2S)-1-amino-1-oxopentan-2-yl]-2-{[(4- 6.4 (1.03)
    bromophenyl)carbamoyl]amino}-4-methylpentanamide
    (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 1.0 (0.89)
    methylpentanoyl]amino}pentanoic acid
    tert-butyl (2S)-2-{[(2S)-2-{[(4- 13 (1.06)
    bromophenyl)carbamoyl]amino}-4-
    methylpentanoyl]amino}pentanoate
    (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-[(2R)-1- 3.0 (1.00)
    hydroxypropan-2-yl]-4-methylpentanamide
    (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2,3- 5.1 (0.98)
    dihydroxypropyl)-4-methylpentanamide
    (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(1,3- 7.4 (0.96)
    dihydroxypropan-2-yl)-4-methylpentanamide
    (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-hydroxy- 2.1 (1.01)
    2-methylpropyl)-4-methylpentanamide
    (2S)-N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-2-{[(4- 1.3 (1.03)
    bromophenyl)carbamoyl]amino}-4-methylpentanamide
    (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 1.83 (1.13)
    methylpentanoyl|amino}-3-methylbutanoic acid
    tert-butyl (2S)-2-{[(2S)-2-{[(4- 68 (0.98)
    bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-
    3-methylbutanoate
    (2S)-N-[(2S)-1-amino-1-oxopropan-2-yl]-2-{[(4- 24 (0.96)
    bromophenyl)carbamoyl]amino}-4-methylpentanamide
    (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 11 (1.05)
    methylpentanoyl]amino}propanoic acid
    tert-butyl (2S)-2-{[(2S)-2-{[(4- 147 (0.96)
    bromophenyl)carbamoyl]amino}-4-
    methylpentanoyl]amino}propanoate
    (2S)-N-[(2S)-1-amino-1-oxopropan-2-yl]-2-{[(4-bromo-2- 31 (1.05)
    fluorophenyl)carbamoyl]amino}-4-methylpentanamide
    (2S)-2-{[(2S)-2-{[(4-bromo-2- 12 (0.95)
    fluorophenyl)carbamoyl]amino}-4-
    methylpentanoyl]amino}propanoic acid
    tert-butyl (2S)-2-{[(2S)-2-{[(4-bromo-2- 174 (1.00)
    fluorophenyl)carbamoyl]amino}-4-
    methylpentanoyl]amino}propanoate
    (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2- 77 (1.05)
    hydroxyethyl)-4-methylpentanamide
    (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4- 20 (0.99)
    methyl-N-(2-oxopropyl)pentanamide
    (2S)-N-(2-amino-2-oxoethyl)-2-{[(4-bromo-2- 4.5 (0.95)
    fluorophenyl)carbamoyl]amino}-4-methylpentanamide
    {[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4- 3.6 (1.10)
    methylpentanoyl]amino}acetic acid
    tert-butyl {[(2S)-2-{[(4-bromo-2- 134 (1.19)
    fluorophenyl)carbamoyl]amino}-4-
    methylpentanoyl]amino}acetate
    (2S)-N-(2-amino-2-oxoethyl)-2-{[(4-bromo-2- 5.2 (0.98)
    fluorophenyl)carbamoyl]amino}pentanamide
    (2S)-N-(2-amino-2-oxoethyl)-2-{[(4- 2.5 (0.97)
    bromophenyl)carbamoyl]amino}pentanamide
    (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methyl-N-(2- 4.7 (0.82)
    oxopropyl)pentanamide
    (2S)-N-(2-amino-2-oxoethyl)-2-{[(4- 1.05 (1.08)
    bromophenyl)carbamoyl]amino}-4-methylpentanamide
    {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 0.88 (0.91)
    methylpentanoyl]amino}acetic acid
    (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2- 11 (0.92)
    hydroxyethyl)-4-methylpentanamide
    tert-butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 140 (0.85)
    methylpentanoyl]amino}acetate
    {[(2S)-2-{[(4-bromo-2- 4.8 (0.92)
    fluorophenyl)carbamoyl]amino}pentanoyl]amino}acetic acid
    tert-butyl {[(2S)-2-{[(4-bromo-2- 83 (0.95)
    fluorophenyl)carbamoyl]amino}pentanoyl]amino}acetate
    (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2- 92 (0.92)
    oxopropyl)pentanamide
    (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2- 35 (1.05)
    oxopropyl)pentanamide
    propan-2-yl {[(2S)-2-{[(4- 14 (1.04)
    bromophenyl)carbamoyl]amino}pentanoyl]amino}acetate
    ethyl {[(2S)-2-{[(4- 57 (1.18)
    bromophenyl)carbamoyl]amino}pentanoyl]amino}acetate
    methyl {[(2S)-2-{[(4- 17 (0.88)
    bromophenyl)carbamoyl]amino}pentanoyl]amino}acetate
    (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2- 105 (0.87)
    hydroxyethyl)pentanamide
    (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2- 38 (0.92)
    hydroxyethyl)pentanamide
    (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2- 16 (0.98)
    hydroxyethyl)-3-phenylpropanamide
    {[(2S)-2-{[(4- 3.2 (0.91)
    bromophenyl)carbamoyl]amino}pentanoyl]amino}acetic acid
    tert-butyl {[(2S)-2-{[(4- 31 (0.95)
    bromophenyl)carbamoyl]amino}pentanoyl]amino}acetate
    (2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2- 12 (0.94)
    oxopropyl)-3-phenylpropanamide
    (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2- 29 (0.96)
    oxopropyl)-3-phenylpropanamide
    (2S,3S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N- 62 (1.00)
    (2-hydroxyethyl)-3-methylpentanamide
    (2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2- 24 (1.00)
    hydroxyethyl)-3-methylpentanamide
    (2S,3S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-3- 36 (1.01)
    methyl-N-(2-oxopropyl)pentanamide
    (2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methyl-N- 10 (0.97)
    (2-oxopropyl)pentanamide
    (2S,3S)-N-(2-amino-2-oxoethyl)-2-{[(4-bromo-2- 10 (1.00)
    fluorophenyl)carbamoyl]amino}-3-methylpentanamide
    (2S,3S)-N-(2-amino-2-oxoethyl)-2-{[(4- 4.6 (0.81)
    bromophenyl)carbamoyl]amino}-3-methylpentanamide
    {[(2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3- 2.7 (1.00)
    methylpentanoyl]amino}acetic acid
    tert-butyl {[(2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}- 280 (0.85)
    3-methylpentanoyl]amino}acetate
    {[(2S,3S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}- 5.5 (0.95)
    3-methylpentanoyl]amino}acetic acid
    tert-butyl {[(2S,3S)-2-{[(4-bromo-2- 757 (0.86)
    fluorophenyl)carbamoyl]amino}-3-
    methylpentanoyl]amino}acetate
    (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2- 6 (0.92)
    hydroxyethyl)-3-phenylpropanamide
    3-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3- 18 (0.98)
    phenylpropanoyl]amino}propanoic acid
    tert-butyl 3-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}- 255 (1.00)
    3-phenylpropanoyl]amino}propanoate
    {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3- 7.7 (0.99)
    phenylpropanoyl]amino}acetic acid
    tert-butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3- 118 (0.91)
    phenylpropanoyl]amino}acetate
    tert-butyl 2-{[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}- 2725 (0.74)
    4-methylpentanoyl]amino}-2-methylpropanoate
    2-{[(2R)-2-{[(4-bromophenyl)carbamoyl]amino}-4- 490 (0.74)
    methylpentanoyl]amino}-2-methylpropanoic acid
    {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H-indol-3- 0.73 (0.97)
    yl)propanoyl]amino}acetic acid
    tert-butyl {[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1H- 305 (1.03)
    indol-3-yl)propanoyl]amino}acetate
    [(4-amino-2-{[(4-bromophenyl)carbamoyl]amino}-4- 2938 (0.81)
    oxobutanoyl)amino]acetic acid
    tert-butyl [(4-amino-2-{[(4-bromophenyl)carbamoyl]amino}- 2306 (0.90)
    4-oxobutanoyl)amino]acetate

Claims (1)

What is claimed is:
1. A pharmaceutical composition comprising a therapeutically effective amount of a compound having the following structure:
Figure US20220202777A1-20220630-C00173
or a pharmaceutically acceptable salt thereof.
US17/229,347 2011-10-26 2021-04-13 Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators Abandoned US20220202777A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/229,347 US20220202777A1 (en) 2011-10-26 2021-04-13 Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161551772P 2011-10-26 2011-10-26
US13/658,523 US8658803B2 (en) 2011-10-26 2012-10-23 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US14/102,145 US8993780B2 (en) 2011-10-26 2013-12-10 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US14/608,503 US9351948B2 (en) 2011-10-26 2015-01-29 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US15/138,823 US9579307B2 (en) 2011-10-26 2016-04-26 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US15/408,643 US9974772B2 (en) 2011-10-26 2017-01-18 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US15/949,335 US10172832B2 (en) 2011-10-26 2018-04-10 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US16/215,400 US10993931B2 (en) 2011-10-26 2018-12-10 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US17/229,347 US20220202777A1 (en) 2011-10-26 2021-04-13 Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/215,400 Continuation US10993931B2 (en) 2011-10-26 2018-12-10 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

Publications (1)

Publication Number Publication Date
US20220202777A1 true US20220202777A1 (en) 2022-06-30

Family

ID=47116500

Family Applications (8)

Application Number Title Priority Date Filing Date
US13/658,523 Active US8658803B2 (en) 2011-10-26 2012-10-23 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US14/102,145 Active US8993780B2 (en) 2011-10-26 2013-12-10 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US14/608,503 Active US9351948B2 (en) 2011-10-26 2015-01-29 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US15/138,823 Active US9579307B2 (en) 2011-10-26 2016-04-26 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US15/408,643 Active US9974772B2 (en) 2011-10-26 2017-01-18 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US15/949,335 Active US10172832B2 (en) 2011-10-26 2018-04-10 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US16/215,400 Active US10993931B2 (en) 2011-10-26 2018-12-10 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US17/229,347 Abandoned US20220202777A1 (en) 2011-10-26 2021-04-13 Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

Family Applications Before (7)

Application Number Title Priority Date Filing Date
US13/658,523 Active US8658803B2 (en) 2011-10-26 2012-10-23 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US14/102,145 Active US8993780B2 (en) 2011-10-26 2013-12-10 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US14/608,503 Active US9351948B2 (en) 2011-10-26 2015-01-29 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US15/138,823 Active US9579307B2 (en) 2011-10-26 2016-04-26 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US15/408,643 Active US9974772B2 (en) 2011-10-26 2017-01-18 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US15/949,335 Active US10172832B2 (en) 2011-10-26 2018-04-10 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US16/215,400 Active US10993931B2 (en) 2011-10-26 2018-12-10 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

Country Status (33)

Country Link
US (8) US8658803B2 (en)
EP (2) EP2770989B1 (en)
JP (3) JP5982001B2 (en)
KR (1) KR102051687B1 (en)
CN (2) CN106518742B (en)
AR (2) AR088535A1 (en)
AU (3) AU2012329098B2 (en)
BR (2) BR122019025505B1 (en)
CA (1) CA2853648C (en)
CL (1) CL2014001080A1 (en)
CO (1) CO6960509A2 (en)
CY (1) CY1121604T1 (en)
DK (1) DK2770989T3 (en)
ES (2) ES2820714T3 (en)
HK (1) HK1199622A1 (en)
HR (1) HRP20181934T1 (en)
HU (1) HUE040145T2 (en)
IL (3) IL232204B (en)
IN (1) IN2014DN03424A (en)
LT (1) LT2770989T (en)
MX (1) MX357737B (en)
MY (1) MY172013A (en)
PH (1) PH12019500171A1 (en)
PL (1) PL2770989T3 (en)
PT (1) PT2770989T (en)
RS (1) RS58111B1 (en)
RU (2) RU2744577C2 (en)
SG (2) SG11201401818RA (en)
SI (1) SI2770989T1 (en)
TW (1) TWI631099B (en)
UA (1) UA115043C2 (en)
WO (1) WO2013062947A1 (en)
ZA (1) ZA201403222B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
ES2820714T3 (en) * 2011-10-26 2021-04-22 Allergan Inc Substituted N-urea amino acid amide derivatives as modulators of formylated peptide receptor 1 (FPRL-1) receptor
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
SG11201507113RA (en) * 2013-03-06 2015-10-29 Allergan Inc Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
CA2899804A1 (en) * 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
ES2708571T3 (en) * 2013-07-16 2019-04-10 Allergan Inc Derivatives of amino acids substituted with N-urea as modulators of the formylated peptide receptor
AR097279A1 (en) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd DERIVATIVES OF BENZIMIDAZOLIL-METIL UREA AS ALX RECEIVER AGONISTS
TWI537251B (en) 2013-10-09 2016-06-11 長庚大學 Fpr1 antagonist derivatives and use thereof
AU2014352922B2 (en) * 2013-11-21 2018-06-07 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
CA2932010C (en) 2013-11-28 2020-07-07 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
EP3145916B1 (en) * 2014-05-21 2020-02-12 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
BR112017024966A2 (en) 2015-05-27 2018-08-07 Kyorin Seiyaku Kk derived from urea or pharmacologically acceptable salt of the same
US10858314B2 (en) * 2015-05-27 2020-12-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
CA2992662A1 (en) * 2015-08-05 2017-02-09 Allergan, Inc. Phenyl urea analogs as formyl peptide repceptor 1 (fpr1) selective agonists
CN109715602A (en) 2016-03-28 2019-05-03 阿勒根公司 Phenyl Urea Derivatives are as N- formyl peptide receptor regulator
EP3442950A1 (en) 2016-04-12 2019-02-20 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
CA3039455A1 (en) 2016-10-06 2018-04-12 Daiichi Sankyo Company, Limited Urea derivative
JP2020015664A (en) * 2016-11-21 2020-01-30 宇部興産株式会社 Nitrogen-containing polycyclic heterocyclic derivative
US10608869B2 (en) * 2017-03-20 2020-03-31 Nicira, Inc. Handling control-plane connectivity loss in virtualized computing environments
KR20200128709A (en) 2018-03-05 2020-11-16 브리스톨-마이어스 스큅 컴퍼니 Phenylpyrrolidinone formyl peptide 2 receptor agonist
EP4234014A1 (en) * 2022-02-28 2023-08-30 Insusense ApS Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658803B2 (en) * 2011-10-26 2014-02-25 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US9850264B2 (en) * 2013-03-06 2017-12-26 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
US10434112B2 (en) * 2013-03-06 2019-10-08 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (en) * 1982-09-17 1984-03-23 Lyon I Universite Claude SWEETENERS OF SYNTHESIS
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
JP3387948B2 (en) 1992-12-04 2003-03-17 富山化学工業株式会社 Novel phenylalanine derivative or salt thereof
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
CA2170766A1 (en) * 1993-11-05 1995-05-11 Gary Louis Bolton Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
JPH11171896A (en) * 1995-09-19 1999-06-29 Kirin Brewery Co Ltd New peptide compound and its pharmaceutical composition
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
US6548637B1 (en) * 1998-06-18 2003-04-15 Sepracor, Inc. Ligands for opioid receptors
US6243689B1 (en) 1998-12-29 2001-06-05 Robert G. Norton System and method for authorizing electronic funds transfer at a point of sale
AU6909300A (en) 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE10063008A1 (en) 2000-12-16 2002-06-20 Merck Patent Gmbh carboxamide
AU2002255485A1 (en) * 2001-01-19 2002-09-12 The Scripps Research Institute Hiv/fiv protease inhibitors
DK1453852T3 (en) * 2001-12-12 2007-05-21 Wilex Ag Selective arylguanidine peptides as urokinase inhibitors
CN100497302C (en) 2002-09-05 2009-06-10 神经研究公司 Diarylurea derivatives and their use as chloride channel blockers
AU2003259007A1 (en) * 2002-10-31 2004-05-25 Amersham Biosciences Ab Use of urea variants as affinity ligands
EP1559721B1 (en) 2002-11-07 2009-11-04 Takeda Pharmaceutical Company Limited Fprl1 ligands and use thereof
KR100527361B1 (en) * 2003-04-01 2005-11-09 주식회사 프로메디텍 A deformylase inhibitor, a process for the preparation thereof, and a composition comprising the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN1894580A (en) * 2003-11-07 2007-01-10 阿卡蒂亚药品公司 The lipoxin receptor, FPRL1, as a tool for identifying compounds effective in the treatment of pain and inflammation
BRPI0416272A (en) * 2003-11-07 2007-01-09 Acadia Pharm Inc fprl1 receptor uses, and compounds, prophylactic use of compounds, screening methods for a compound capable of affecting one or more activities of a fprl1 receptor, treating or preventing inflammation, identifying a vasodilation inducing compound, to antagonism of a vasoconstructive response to a leukotriene sulfidopeptide in an individual, and to stimulation of cell proliferation in an individual, and, compound
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
GB0417802D0 (en) 2004-08-10 2004-09-15 Novartis Ag Organic compounds
JP2008518913A (en) 2004-10-28 2008-06-05 メルク エンド カムパニー インコーポレーテッド Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
WO2006063113A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. Ureas as factor xa inhibitors
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US8349801B2 (en) 2006-09-18 2013-01-08 Compugen Ltd. Peptide ligands for G-protein coupled receptors
AR065093A1 (en) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd PHARMACEUTICAL COMPOUNDS INHIBITING THE BIOSYNTHESIS OF LEUCOTRIENS
KR20090121832A (en) 2008-05-23 2009-11-26 인제대학교 산학협력단 2-(2-hydroxybenzoyl)hydrazinecarboxamide derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and phrmaceutical composition for the immunosuppression containing the same as an active ingredient
US20100035932A1 (en) 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
CA2747995A1 (en) * 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
AU2011270872A1 (en) 2010-06-24 2013-01-31 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
CA2819457A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
EP2673263A1 (en) 2011-02-11 2013-12-18 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
EP2720691A1 (en) 2011-06-17 2014-04-23 Allergan, Inc. D -serine for the treatment of visual system disorders
GB2494851A (en) * 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
CA2841983A1 (en) 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
CA2864893A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators
CN104302630A (en) 2012-04-16 2015-01-21 阿勒根公司 (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
ES2708571T3 (en) 2013-07-16 2019-04-10 Allergan Inc Derivatives of amino acids substituted with N-urea as modulators of the formylated peptide receptor
US20150080466A1 (en) 2013-09-19 2015-03-19 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
GB2533536B (en) 2013-10-24 2021-05-19 Toyota Motor Co Ltd Cathode active material for sodium batteries, and sodium battery
AU2014352922B2 (en) 2013-11-21 2018-06-07 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
EP3145916B1 (en) 2014-05-21 2020-02-12 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658803B2 (en) * 2011-10-26 2014-02-25 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US9351948B2 (en) * 2011-10-26 2016-05-31 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US9579307B2 (en) * 2011-10-26 2017-02-28 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US9974772B2 (en) * 2011-10-26 2018-05-22 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US10172832B2 (en) * 2011-10-26 2019-01-08 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US10993931B2 (en) * 2011-10-26 2021-05-04 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US9850264B2 (en) * 2013-03-06 2017-12-26 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
US10434112B2 (en) * 2013-03-06 2019-10-08 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
US10799518B2 (en) * 2013-03-06 2020-10-13 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts Service STN Registry Database, Registry Nos: 1042104-83-5, 1041439-56-8, 1041011-06-6, 1041005-31-5, and 1040746-33-5 (Entered STN: August 2008). (Year: 2008) *

Also Published As

Publication number Publication date
BR112014010042B1 (en) 2022-03-03
WO2013062947A1 (en) 2013-05-02
AU2019264555B2 (en) 2020-12-17
JP2014534216A (en) 2014-12-18
US10172832B2 (en) 2019-01-08
HRP20181934T1 (en) 2019-01-25
AU2012329098B2 (en) 2017-08-03
KR20140111646A (en) 2014-09-19
IL256555A (en) 2018-02-28
US20170119737A1 (en) 2017-05-04
SG10201903266YA (en) 2019-05-30
US9579307B2 (en) 2017-02-28
AR088535A1 (en) 2014-06-18
US20140094614A1 (en) 2014-04-03
AU2019264555A1 (en) 2019-12-05
AU2012329098A1 (en) 2014-05-22
MY172013A (en) 2019-11-12
CA2853648A1 (en) 2013-05-02
AU2017251683A1 (en) 2017-11-09
EP3078656B1 (en) 2020-07-01
DK2770989T3 (en) 2018-12-17
IL232204B (en) 2018-12-31
US10993931B2 (en) 2021-05-04
IL256555B (en) 2020-07-30
PH12019500171A1 (en) 2020-06-15
US8993780B2 (en) 2015-03-31
US20150148395A1 (en) 2015-05-28
ES2820714T3 (en) 2021-04-22
EP3078656A1 (en) 2016-10-12
MX2014005047A (en) 2015-09-04
CN106518742B (en) 2020-01-21
CN104114164B (en) 2016-11-16
CO6960509A2 (en) 2014-05-30
RU2744577C2 (en) 2021-03-11
JP2016216497A (en) 2016-12-22
IN2014DN03424A (en) 2015-06-05
CY1121604T1 (en) 2020-05-29
BR112014010042A8 (en) 2017-06-20
BR112014010042A2 (en) 2017-06-13
AU2017251683B2 (en) 2019-08-15
TW201331168A (en) 2013-08-01
US9351948B2 (en) 2016-05-31
BR122019025505B1 (en) 2022-02-22
TWI631099B (en) 2018-08-01
KR102051687B1 (en) 2019-12-17
LT2770989T (en) 2018-12-10
IL267659B (en) 2021-10-31
US8658803B2 (en) 2014-02-25
HUE040145T2 (en) 2019-02-28
RU2014120013A (en) 2015-12-10
PL2770989T3 (en) 2019-01-31
CA2853648C (en) 2023-01-24
SI2770989T1 (en) 2018-12-31
US20160235711A1 (en) 2016-08-18
RU2017129434A (en) 2019-02-04
AR119698A2 (en) 2022-01-05
MX357737B (en) 2018-07-23
US20190343804A1 (en) 2019-11-14
JP6496689B2 (en) 2019-04-03
PT2770989T (en) 2018-12-04
EP2770989B1 (en) 2018-09-05
UA115043C2 (en) 2017-09-11
CN106518742A (en) 2017-03-22
SG11201401818RA (en) 2014-05-29
JP6804580B2 (en) 2020-12-23
US9974772B2 (en) 2018-05-22
RU2629205C2 (en) 2017-08-25
RU2017129434A3 (en) 2020-10-09
US20180228772A1 (en) 2018-08-16
CN104114164A (en) 2014-10-22
ES2708997T3 (en) 2019-04-12
IL232204A0 (en) 2014-06-30
NZ624635A (en) 2017-01-27
CL2014001080A1 (en) 2014-11-14
EP2770989A1 (en) 2014-09-03
JP2019089849A (en) 2019-06-13
RS58111B1 (en) 2019-02-28
IL267659A (en) 2019-08-29
AU2017251683C1 (en) 2019-11-14
JP5982001B2 (en) 2016-08-31
HK1199622A1 (en) 2015-07-10
ZA201403222B (en) 2015-07-29
US20130109866A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
US10993931B2 (en) Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8541577B2 (en) Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US9428549B2 (en) Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
US20150080466A1 (en) Diphenyl urea derivatives as formyl peptide receptor modulators
NZ624635B2 (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLERGAN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEARD, RICHARD L.;DUONG, TIEN T.;GARST, MICHAEL E.;AND OTHERS;SIGNING DATES FROM 20121130 TO 20121210;REEL/FRAME:055915/0348

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION